<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis - Aslam, AA - 2023 | Cochrane Library</title> <meta content="Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis - Aslam, AA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012040.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis - Aslam, AA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012040.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012040.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis" name="citation_title"/> <meta content="Aisha A Aslam" name="citation_author"/> <meta content="Royal London Hospital" name="citation_author_institution"/> <meta content="Ian P Sinha" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Kevin W Southern" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="kwsouth@liverpool.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012040.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012040.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012040.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012040.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminoglycosides; Anti-Bacterial Agents; *Codon, Nonsense; *Cystic Fibrosis [drug therapy, genetics]; Cystic Fibrosis Transmembrane Conductance Regulator [genetics]; Mutation; Persistent Infection" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012040.pub3&amp;doi=10.1002/14651858.CD012040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="UiM8QuvV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012040\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012040\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012040.pub3",title:"Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis",firstPublishedDate:"Mar 3, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012040.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012040.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012040.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012040.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012040.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012040.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012040.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012040.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012040.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012040.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>989 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012040.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/appendices#CD012040-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/supinfo/CD012040StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/supinfo/CD012040StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information#CD012040-cr-0004">Aisha A Aslam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information#CD012040-cr-0005">Ian P Sinha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information#CD012040-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Kevin W Southern</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information/en#CD012040-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012040.pub3">https://doi.org/10.1002/14651858.CD012040.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012040-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012040-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012040-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012040-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012040-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012040-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012040-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012040-abs-0001" lang="en"> <section id="CD012040-sec-0001"> <h3 class="title" id="CD012040-sec-0001">Background</h3> <p>Cystic fibrosis (CF) is a common, life‐shortening, genetic disorder in populations of Northern European descent caused by the mutation of a single gene that codes for the production of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This protein coordinates the transport of salt (and bicarbonate) across cell surfaces, and the mutation most notably affects the airways. In the lungs of people with CF, the defective protein compromises mucociliary clearance and makes the airway prone to chronic infection and inflammation, damaging the structure of the airways and eventually leading to respiratory failure. In addition, abnormalities in the truncated CFTR protein lead to other systemic complications, including malnutrition, diabetes and subfertility. </p> <p>Five classes of mutation have been described, depending on the impact of the mutation on the processing of the CFTR protein in the cell. In class I mutations, premature termination codons prevent the production of any functional protein, resulting in severe CF. Therapies targeting class I mutations aim to enable the normal cellular mechanism to read through the mutation, potentially restoring the production of the CFTR protein. This could, in turn, normalise salt transport in the cells and decrease the chronic infection and inflammation that characterises lung disease in people with CF. </p> <p>This is an update of a previously published review.</p> </section> <section id="CD012040-sec-0002"> <h3 class="title" id="CD012040-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of ataluren and similar compounds on clinically important outcomes in people with CF with class I mutations (premature termination codons). </p> </section> <section id="CD012040-sec-0003"> <h3 class="title" id="CD012040-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis Trials Register, which is compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles. The last search of the Cochrane Cystic Fibrosis Trials Register was conducted on 7 March 2022. </p> <p>We searched clinical trial registries maintained by the European Medicines Agency, the US National Institutes of Health and the World Health Organization. The last search of the clinical trials registries was conducted on 4 October 2022. </p> </section> <section id="CD012040-sec-0004"> <h3 class="title" id="CD012040-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of parallel design comparing ataluren and similar compounds (specific therapies for class I mutations) with placebo in people with CF who have at least one class I mutation. </p> </section> <section id="CD012040-sec-0005"> <h3 class="title" id="CD012040-sec-0005">Data collection and analysis</h3> <p>For the included trials, the review authors independently extracted data, assessed the risk of bias and evaluated the certainty of the evidence using GRADE; trial authors were contacted for additional data. </p> </section> <section id="CD012040-sec-0006"> <h3 class="title" id="CD012040-sec-0006">Main results</h3> <p>Our searches identified 56 references to 20 trials; of these, 18 trials were excluded. Both the included parallel RCTs compared ataluren to placebo for 48 weeks in 517 participants (males and females; age range six to 53 years) with CF who had at least one nonsense mutation (a type of class I mutation). </p> <p>The certainty of evidence and risk of bias assessments for the trials were moderate overall. Random sequence generation, allocation concealment and blinding of trial personnel were well documented; participant blinding was less clear. Some participant data were excluded from the analysis in one trial that also had a high risk of bias for selective outcome reporting. PTC Therapeutics Incorporated sponsored both trials with grant support from the Cystic Fibrosis Foundation, the US Food and Drug Administration's Office of Orphan Products Development and the National Institutes of Health. </p> <p>The trials reported no difference between treatment groups in terms of quality of life, and no improvement in respiratory function measures. Ataluren was associated with a higher rate of episodes of renal impairment (risk ratio 12.81, 95% confidence interval 2.46 to 66.65; P = 0.002; I<sup>2</sup> = 0%; 2 trials, 517 participants). The trials reported no treatment effect for ataluren for the review's secondary outcomes of pulmonary exacerbation, computed tomography score, weight, body mass index and sweat chloride. No deaths were reported in the trials. </p> <p>The earlier trial performed a post hoc subgroup analysis of participants not receiving concomitant chronic inhaled tobramycin (n = 146). This analysis demonstrated favourable results for ataluren (n = 72) for the relative change in forced expiratory volume in one second (FEV<sub>1</sub>) per cent (%) predicted and pulmonary exacerbation rate. The later trial aimed to prospectively assess the efficacy of ataluren in participants not concomitantly receiving inhaled aminoglycosides, and found no difference between ataluren and placebo in FEV<sub>1</sub> % predicted and pulmonary exacerbation rate.  </p> </section> <section id="CD012040-sec-0007"> <h3 class="title" id="CD012040-sec-0007">Authors' conclusions</h3> <p>There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with CF with class I mutations. One trial reported favourable results for ataluren in a post hoc subgroup analysis of participants not receiving chronic inhaled aminoglycosides, but these were not reproduced in the later trial, suggesting that the earlier results may have occurred by chance. Future trials should carefully assess for adverse events, notably renal impairment, and consider the possibility of drug interactions. Cross‐over trials should be avoided, given the potential for the treatment to change the natural history of CF. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012040-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012040-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012040-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012040-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012040-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012040-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012040-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012040-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012040-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012040-abs-0002" lang="en"> <h3>Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis </h3> <p><b>Review question</b> </p> <p>Can ataluren (and similar compounds specifically targeting class I mutations in cystic fibrosis (CF)) improve the quality of life and lung function of people with CF without having adverse effects? </p> <p><b>Key messages</b> </p> <p>What is CF? </p> <p>In people with CF, the gene encoding a protein called the cystic fibrosis transmembrane conductance regulator (CFTR) is faulty. This especially affects the airways, causing the airway surface to dry out and making it difficult to clear thick mucus. This leads to progressive infection and damages the lungs, shortening life expectancy. </p> <p>How will ataluren treat CF? </p> <p>In people with certain CF genetic mutations where the genetic instructions for producing  the CFTR protein are interrupted (known as premature termination codon or class I mutations), ataluren (and similar medicines) may be able to skip over the break in the faulty gene sequence and allow the body to produce a corrected version of the CFTR protein. By correcting the protein, the airway surface should remain hydrated, allowing people with CF to better clear their mucus and so develop fewer lung infections. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know whether ataluren can improve the quality of life and lung function of people with CF, and whether it can do so without any side effects. We also wanted to measure the effects on lung infections (need for hospital visits or additional antibiotics), survival, nutritional status (weight, body mass index and height) and whether treatment was cost‐effective. </p> <p><b>What did we do?</b> </p> <p>We searched for trials that directly compared drugs such as ataluren to placebo (treatment not containing an active drug) or to a different treatment for these specific genetic mutations in any people with CF. </p> <p><b>What did we find?</b> </p> <p>We found two trials including 517 people (males and females between 6 and 53 years of age) comparing ataluren to a placebo. The trials lasted 48 weeks and everyone taking part in the trials had at least one gene with a class I mutation. </p> <p><b>Key results</b> </p> <p>In people taking ataluren, there was no improvement in clinical outcomes such as quality of life, lung function, exacerbations (flare up of disease), sweat chloride (salt) levels or weight compared with people taking placebo. The trials found that kidney damage was more common in people taking ataluren.  </p> <p>The earlier trial analysed their results in a way not originally planned to see whether the effects of ataluren and placebo were different in people using inhaled tobramycin (an antibiotic) on a long‐term basis compared with people not taking the inhaled antibiotic. In people taking ataluren but not using inhaled tobramycin, lung function declined at a slower rate and there were fewer exacerbations than in people in the placebo group also not using inhaled tobramycin. The later trial specifically recruited people not taking tobramycin to see whether this really was an effect of the antibiotic, but the investigators did not find any difference between the ataluren and placebo groups for changes in lung function or exacerbations. This suggests that the earlier results occurred by chance. </p> <p>There were no deaths and we did not find any differences between ataluren and placebo in side effects or nutritional status. Neither trial reported on hospitalisations, extra courses of antibiotics or cost‐effectiveness. </p> <p>We have not found enough high‐quality evidence to determine the effect of ataluren for treating CF. We recommend that future trials are designed and reported clearly so that their results can be included in a systematic review. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident in our findings, but there is some uncertainty due to how widely the results varied between participants. We are satisfied that everyone taking part had an equal chance of being in either group (ataluren or placebo) and that no one could work out which group the next person would be put into (so that healthier people did not receive the treatment and make the results seem better). We believe that the clinicians running the trials and those taking part in the trials did not know which treatment each person was receiving. We have some concerns about the emphasis the investigators of one trial placed on the results of a comparison they had not planned (the use of long‐term inhaled tobramycin). Unfortunately, that trial did not report all its results clearly. Sometimes, the results were reported in a way that meant they could not be used in this review, and sometimes the information was not reported at all. This affected our confidence in the overall results. </p> <p><b>Trial funding sources</b> </p> <p>Both trials were sponsored by PTC Therapeutics Incorporated, who make ataluren. The Cystic Fibrosis Foundation, the US Food and Drug Administration's Office of Orphan Products Development and the US National Institutes of Health also supported the trials. </p> <p><b>How up to date is this evidence?</b> </p> <p>We last searched for evidence on 4 October 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012040-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012040-sec-0098"></div> <h3 class="title" id="CD012040-sec-0099">Implications for practice</h3> <section id="CD012040-sec-0099"> <p>There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with cystic fibrosis (CF) with class I mutations. Ataluren was associated with a higher rate of episodes of renal impairment, the degree of which requires further information. </p> </section> <h3 class="title" id="CD012040-sec-0100">Implications for research</h3> <section id="CD012040-sec-0100"> <p>It is important that future trials assess outcomes to determine the long‐term use of ataluren in terms of both efficacy and tolerability. Future trials should be powered to detect a difference not only in relative change from baseline in forced expiratory volume in one second (FEV<sub>1</sub>), but also in quality of life (QoL) and adverse events, outcomes of significant importance to people with CF. In particular, the clear reporting of adverse events is critical, with particular attention to episodes of renal impairment and nephrolithiasis. Criteria for any grading classifications used when reporting adverse events should be clearly stated. </p> <p>Given the chronic nature of CF, it is important that the burden of additional treatment to people's current regimen is examined, as well as the potential impact of new therapies on adherence to existing CF medications. </p> <p>Cross‐over trials should be avoided, given the potential for the treatment to change the natural history of CF. Furthermore, future trials should be large enough to enable detailed analysis of the effectiveness of ataluren in population subgroups (e.g. adults and children). </p> <p>Currently, there are no trials comparing ataluren to treatment with other compounds for class I mutations (premature termination codons (PTCs)) in CF. Further research examining the interaction of tobramycin and ataluren is required; in particular, characterising the potential of tobramycin to cause read‐through of PTCs. </p> <p>The initial promise of other PTC‐type agents has not progressed; although a number of targets have been explored by pharmaceutical companies, we are not aware of any active drug development pipelines in this field. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012040-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012040-sec-0008"></div> <div class="table" id="CD012040-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ataluren versus placebo for people with cystic fibrosis with class I mutations (PTCs)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ataluren versus placebo for people with cystic fibrosis with class I mutations (PTCs)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> adults and children with CF with at least one class I mutation (PTC) </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> oral ataluren 40 mg/kg/day (in divided doses)  </p> <p><b>Comparison:</b> oral placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of </b> </p> <p><b>the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ataluren</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life: </b> </p> <p>mean change from baseline in </p> <p>CFQ‐R respiratory domain score </p> <p>Scale: age‐appropriate versions of the</p> <p>CFQ‐R questionnaire</p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between groups in CFQ‐R score.</p> <p> </p> <p>One trial reported that the score was 0.27 points higher in the ataluren group (3.55 points lower  </p> <p>to 4.10 points higher).</p> <p> </p> <p>The second trial reported no difference in CFQ‐R in either the 6‐ to 13‐year age group or the 14‐years‐and‐over age group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>506</p> <p>(2 studies)<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> <p> </p> <p>The second trial did not present data for analysis and we have reported their results directly from the paper. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function:</b> </p> <p>FEV<sub>1</sub> % predicted (relative change from baseline) </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) relative change from baseline in the placebo group was ‐5.5% (12.56%).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean relative change from baseline in the ataluren group was 2.97% higher (0.58 lower to 6.52 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> <p> </p> <p>We were unable to combine results for this outcome, but we were able to combine the results in one of the subgroup analyses. </p> <p>In the group of participants not receiving chronic inhaled aminoglycosides, the combined data showed no difference between groups (MD 1.84%, 95% CI ‐0.90 to 4.58; P = 0.19, I<sup>2</sup> = 65%; 2 trials, 399 participants). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events relating to treatment</b> </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Acute kidney injury was more common in the ataluren group (RR 12.81, 95% CI 2.46 to 66.65; P = 0.02; 2 trials, 517 participants). </p> <p> </p> <p>Oropharyngeal pain was more common in the ataluren group (RR 0.28, 95% CI 0.10 to 0.83; P = 0.02; 1 trial, 238 participants). </p> <p> </p> <p>There was no difference between groups for any other adverse events relating to treatment, including: diarrhoea; abdominal pain; vomiting; nausea; pyrexia; upper respiratory tract infections; sinusitis; rhinitis; headache; pulmonary exacerbation; cough; haemoptysis; nasopharyngitis; influenza; pharyngitis; and nephrolithiasis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were graded by severity (1 to 4); however, details of criteria for grade 1 to 3 classifications were not reported. Adverse events occurring in more than 10% of participants were reported. There was no difference between treatment groups for all other recorded adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary exacerbations: protocol‐defined </b> </p> <p> </p> <p>Scale: rate </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) protocol‐defined pulmonary exacerbation rate using modified Fuchs' criteria in the placebo group was 1.78 (2.15). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protocol‐defined pulmonary exacerbation rate using modified Fuchs' criteria in the ataluren groups was 0.36 lower (0.89 lower to 0.17 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) protocol‐defined pulmonary exacerbation rate using expanded Fuchs' criteria in the placebo group was 1.13 (2.52). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protocol‐defined pulmonary exacerbation rate using expanded Fuchs' criteria in the ataluren groups was 0.18 lower (0.66 lower to 0.30 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nutrition and growth:</b> change in weight (kg), BMI (kg/m<sup>2</sup>) or height (m) </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No differences were found between treatment groups for changes in body weight or BMI.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>506</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> <p> </p> <p>One trial reported data for BMI (MD ‐0.07, 95% CI ‐0.32 to 0.19); the second trial reported narratively. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sweat chloride level ‐ change from baseline</b> </p> <p> </p> <p>Scale: mmol/L</p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in the placebo group was ‐0.6 (10.27) mmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the ataluren group was 0.70 mmol/L lower (3.41 mmol/L lower to 2.01 mmol/L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality rate</b> </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Both trials reported zero deaths in both treatment groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI:</b> body mass index; <b>CF</b> : cystic fibrosis; <b>CFQ‐R</b>: Cystic Fibrosis Questionnaire ‐ Revised (<a href="./references#CD012040-bbs2-0037" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8. [DOI: 10.1378/chest.08-1190]">Quittner 2009</a>); <b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>ITT</b> : intention‐to‐treat; <b>MD</b> : mean difference; <b>MMRM</b> : mixed‐model repeated‐measures analysis (based on the average effect across all post‐baseline visits); <b>PTC</b> : premature termination codon; <b>RR</b> : risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> stated that 238 participants were randomised, 232 were included in the ITT population and 203 completed the study. It is unclear how many participants were evaluated for the outcome.<br/><sup>b</sup><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> provided insufficient data to conduct analyses.<br/><sup>c</sup>Downgraded due to imprecision demonstrated by wide CIs. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012040-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012040-sec-0009"></div> <p>A glossary of terms specific to this review can be found in <a href="./appendices#CD012040-sec-0104">Appendix 1</a>. A more general glossary of terms used in Cochrane systematic reviews can be accessed at <a href="http://community.cochrane.org/sites/default/files/uploads/glossary.pdf" target="_blank">Cochrane Glossary</a>. </p> <section id="CD012040-sec-0010"> <h3 class="title" id="CD012040-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is a common, life‐shortening, genetic disorder in populations of Northern European descent (less common in other ethnic groups (<a href="./references#CD012040-bbs2-0026" title="FarrellP , FérecC , MacekM , FrischerT , RennerS , RissK , et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics2018;26(12):1832-9. [DOI: 10.1038/s41431-018-0234-z]">Farrell 2018</a>). In the UK, around one in 3000 newborn infants are affected and, in 2013, the median predicted survival was reported as just over 36 years of age (<a href="./references#CD012040-bbs2-0040" title="CF TrustUK . Cystic fibrosis our focus. UK cystic fibrosis registry annual data report 2013. www.cysticfibrosis.org.uk/sites/default/files/2020-12/2014%20Registry%20Annual%20Data%20Report%20SUMMARY.pdf (accessed 15 March 2015).">UK CF Trust 2014</a>; <a href="./references#CD012040-bbs2-0042" title="WelshMJ , RamseyBW , AccursoF , CuttingG . Cystic fibrosis. In: ScriverCR , BeaudetAL , SlyWS , ValleD , editors(s). The Metabolic and Molecular Basis of Inherited Diseases. 8th edition. New York: McGraw-Hill, 2001:5121–88.">Welsh 2001</a>). The condition is caused by the mutation of a single gene, which codes for the production of the cystic fibrosis transmembrane conductance regulator (CFTR) protein (<a href="./references#CD012040-bbs2-0042" title="WelshMJ , RamseyBW , AccursoF , CuttingG . Cystic fibrosis. In: ScriverCR , BeaudetAL , SlyWS , ValleD , editors(s). The Metabolic and Molecular Basis of Inherited Diseases. 8th edition. New York: McGraw-Hill, 2001:5121–88.">Welsh 2001</a>). After transcription (being produced in the centre of the cell), the protein is transported to the cell membrane, where it has an important role as a chloride channel, coordinating the transport of salt across cell surfaces (<a href="./references#CD012040-bbs2-0021" title="BoucherRC . Cystic fibrosis: A disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine2007;13(6):231–40.">Boucher 2007</a>). </p> <p>Lung disease is the major cause of morbidity and mortality in CF (<a href="./references#CD012040-bbs2-0024" title="DavisPB . Cystic fibrosis since 1938. American Journal of Respiratory and Critical Care Medicine2006;173(5):475-82.">Davis 2006</a>). In the airways, the CFTR protein does not function correctly, resulting in increased fluid and sodium resorption away from the airway surface; this, in turn, leads to a dehydrated airway surface liquid and compromised clearance of secretions (<a href="./references#CD012040-bbs2-0021" title="BoucherRC . Cystic fibrosis: A disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine2007;13(6):231–40.">Boucher 2007</a>). The resulting thick mucus in the airway provides a site for infection. Chronic airway infection and inflammation damage the structure of the airways, eventually resulting in respiratory failure. </p> <p>Approximately 2000 mutations of the <i>CFTR</i> gene have been described. Five classes of mutation have been characterised, depending on the impact of the mutation on the processing of the CFTR protein in the cell (<a href="./references#CD012040-bbs2-0022" title="Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto, Canada. Cystic fibrosis mutation database. www.genet.sickkids.on.ca/StatisticsPage.html (accessed 15 March 2015).">CFMD 2011</a>) (<a href="#CD012040-tbl-0002">Table 1</a>). </p> <div class="table" id="CD012040-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of mutations affecting CFTR production, structure and function</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Class</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Example mutation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Impact on CFTR structure and function</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G542X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the presence of a premature termination codon in the nucleotide sequence. Individuals have no CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phe508del (ΔF508)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A full‐length CFTR protein is produced, but is structurally abnormal and destroyed by the cell before it reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Individuals have no CFTR function under normal conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G551D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond ('switch on') to normal stimulation from the cell. This means there is no significant ion transport across the membrane. Individuals have no CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R347P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFTR is transported to the outer cell membrane and responds to normal stimulation, but functions at a low level because chloride ions do not cross the channel appropriately. Individuals have some residual CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A455E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual CFTR function. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CFTR: cystic fibrosis transmembrane conductance regulator</p> </div> </div> <p>This review focuses on class I mutations, which stop the normal protein‐producing mechanisms of the cell, meaning that no significant amounts of CFTR protein are produced. These mutations change the sequence of the <i>CFTR</i> gene, with a piece of DNA inserted telling cells to stop producing the protein. The normal process of producing a protein in the cell is called 'transcription', and this is faulty in class I mutations. There are different ways class I mutations cause this effect: they can insert a sequence of DNA that makes no sense (a nonsense mutation) or they can produce a sequence that directs the normal cellular mechanism to stop (a stop codon mutation). Collectively, these different types of mutation are known as premature termination codons (PTCs), but they essentially have the same outcome of no functional protein being produced (<a href="./references#CD012040-bbs2-0027" title="FriedmanY . Building Biotechnology. 4th edition. Washington DC: Logo Press, 2014.">Friedman 2014</a>; <a href="./references#CD012040-bbs2-0034" title="McElroySP , NomuraT , TorrieLS , WarbrickE , GartnerU , WoodG , et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biology2013;11(6):1-8.">McElroy 2013</a>; <a href="./references#CD012040-bbs2-0036" title="NicholsonP , MühlemannO . Cutting the nonsense: the degradation of PTC-containing mRNAs. Biochemical Society Transactions2010;38(6):1615-20. [DOI: 10.1042/BST0381615]">Nicholson 2010</a>). </p> <p>Class I mutations are seen in approximately 10% of people with CF (with higher proportions seen in the Ashkenazi Jewish population) and result in a severe CF phenotype, with no significant functional protein being synthesised (<a href="./references#CD012040-bbs2-0033" title="KeremB , Chiba-FalekO , KeremE . Cystic fibrosis in Jews: frequency and mutation distribution. Genetic Testing1997;1(1):35-9.">Kerem 1997</a>; <a href="./references#CD012040-bbs2-0035" title="McKoneEF , GossCH , AitkenML . CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest2006;130(5):1441-7.">McKone 2006</a>). </p> </section> <section id="CD012040-sec-0011"> <h3 class="title" id="CD012040-sec-0011">Description of the intervention</h3> <p>Advances in the understanding of the molecular genetics of CF have led to the development of novel mutation‐specific therapies. One potential strategy has been to correct class I mutations (PTCs) by using drugs that mask the abnormal gene sequence of the mutation and enable the normal cellular mechanism to read through the mutation and produce a full‐length protein. The CFTR protein would then be transported normally to the cell membrane, where it might correct the CF salt transport defect. </p> <p>Previous studies have demonstrated that aminoglycoside antibiotics (e.g. gentamicin) have the ability to read through class I mutations (PTCs), resulting in the expression of full‐length CFTR protein and significant changes in the salt‐transporting defect towards normal (<a href="./references#CD012040-bbs2-0023" title="ClancyJP , BebökZ , RuizF , KingC , JonesJ , WalkerL , et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2001;163(7):1683-92.">Clancy 2001</a>; <a href="./references#CD012040-bbs2-0032" title="HowardM , FrizzellRA , BedwellDM . Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine1996;2(4):467-9.">Howard 1996</a>; <a href="./references#CD012040-bbs2-0043" title="WilschanskiM ,  YahavY ,  YaacovY ,  BlauH ,  BenturL ,  RivlinJ , et al. Gentamicin induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine2003;349(15):1433-41.">Wilschanski 2003a</a>). Although gentamicin is widely used as an antibiotic for people with CF, it is not an ideal agent for long‐term treatment because of concerns over renal and ototoxicity (<a href="./references#CD012040-bbs2-0043" title="WilschanskiM ,  YahavY ,  YaacovY ,  BlauH ,  BenturL ,  RivlinJ , et al. Gentamicin induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine2003;349(15):1433-41.">Wilschanski 2003a</a>). </p> <p>High‐throughput screening has identified a molecule called ataluren (formerly PTC124), which has potential as an oral class I (PTC) therapy (<a href="./references#CD012040-bbs2-0034" title="McElroySP , NomuraT , TorrieLS , WarbrickE , GartnerU , WoodG , et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biology2013;11(6):1-8.">McElroy 2013</a>; <a href="./references#CD012040-bbs2-0041" title="WelchEM , BartonER , ZhuoJ , TomizawaY , FriesenWJ , TrifillisP , et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature2007;447(7140):87-91.">Welch 2007</a>). In the laboratory, ataluren has been shown to have the ability to enable the read through of class I (PTC) mutations (<a href="./references#CD012040-bbs2-0041" title="WelchEM , BartonER , ZhuoJ , TomizawaY , FriesenWJ , TrifillisP , et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature2007;447(7140):87-91.">Welch 2007</a>). </p> </section> <section id="CD012040-sec-0012"> <h3 class="title" id="CD012040-sec-0012">How the intervention might work</h3> <p>By correcting the underlying molecular genetic defect, ataluren and related compounds may reverse the abnormal salt transport that characterises CF. This may restore the ability of the airway to prevent airway infection and inflammation and improve respiratory function. In addition, as a systemic treatment, ataluren may have an effect on other parts of the body that are impacted by the CF salt transport defect. </p> </section> <section id="CD012040-sec-0013"> <h3 class="title" id="CD012040-sec-0013">Why it is important to do this review</h3> <p>A number of different mutation‐specific therapies are under investigation. These therapies include potentiators, which improve the compromised function of the CFTR protein that has reached the cell membrane (class III and IV mutations), and correctors, which increase the amount of CFTR protein in the cell membrane (class II mutations) (<a href="#CD012040-tbl-0002">Table 1</a>). Cochrane Reviews assessing both potentiator and corrector therapies have already been published (<a href="./references#CD012040-bbs2-0038" title="SkiltonM , KrishanA , PatelS , SinhaIP , SouthernKW . Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD009841. [DOI: 10.1002/14651858.CD009841.pub3]">Skilton 2019</a>; <a href="./references#CD012040-bbs2-0039" title="SouthernKW , MurphyJ , SinhaIP , NevittSJ . Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD010966. [DOI: 10.1002/14651858.CD010966.pub3]">Southern 2020</a>). At present, there are no known trials for therapies specific to class V mutations. </p> <p>It is important that the randomised controlled trials (RCTs) assessing ataluren or similar compounds are critically appraised. This will allow analysis of the data outlining the benefits and harms of these therapies in people with CF. It is important that funding bodies have a clear evidence base on which to assess novel mutation‐specific CF therapies. It is likely that these therapies will represent a significant healthcare resource. In addition, a critical appraisal of included trials will help inform future trial design. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012040-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012040-sec-0014"></div> <p>To evaluate the benefits and harms of ataluren and similar compounds on clinically important outcomes in people with CF with class I mutations (premature termination codons). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012040-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012040-sec-0015"></div> <section id="CD012040-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012040-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs of parallel design (published or unpublished). We excluded quasi‐RCTs due to a greater risk of selection bias. We reviewed cross‐over trials individually to evaluate whether data from the first treatment arm could be included; however, because these therapies aim to correct the underlying gene defect, there is significant potential for longer‐term impact on outcomes, and this is not an ideal trial design. </p> </section> <section id="CD012040-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials involving children or adults with CF, of any severity, as confirmed by either the presence of two disease‐causing mutations or a combination of a positive sweat test and recognised clinical features of CF. We only included trials in which participants had at least one PTC (nonsense or stop codon) mutation. </p> </section> <section id="CD012040-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials in which ataluren (or a similar compound for PTC class I mutations) was compared with either placebo or another intervention. We excluded trials that combined therapies for PTC class I mutations with other mutation‐specific therapies. No trials comparing different dosing regimens of these therapies were eligible for inclusion based on the aforementioned criteria. In future updates, we will include trials comparing different dosing regimens of therapies for PTC class I mutations if we identify such trials. </p> </section> <section id="CD012040-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012040-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012040-list-0001"> <li> <p>Quality of life (QoL; measured using validated quantitative scales or scores (e.g. Cystic Fibrosis Questionnaire ‐ Revised (CFQ‐R) (<a href="./references#CD012040-bbs2-0037" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8. [DOI: 10.1378/chest.08-1190]">Quittner 2009</a>)) </p> <ol id="CD012040-list-0002"> <li> <p>Total QoL score</p> </li> <li> <p>Different subdomains</p> </li> </ol> </li> <li> <p>Measures of respiratory function (litres or per cent (%) predicted for age, sex and height) </p> <ol id="CD012040-list-0003"> <li> <p>Forced expiratory flow rate in one second (FEV<sub>1</sub>; relative change from baseline) </p> </li> <li> <p>FEV<sub>1</sub> (absolute values) </p> </li> <li> <p>Forced vital capacity (FVC; absolute values and relative change from baseline)</p> </li> </ol> </li> <li> <p>Adverse events</p> <ol id="CD012040-list-0004"> <li> <p>Graded by review authors as mild (therapy does not need to be discontinued)</p> </li> <li> <p>Graded by review authors as moderate (therapy is discontinued and the adverse effect ceases) </p> </li> <li> <p>Graded by review authors as severe (life‐threatening or debilitating effects or those that persist even after treatment is discontinued) </p> </li> </ol> </li> </ol> </p> </section> <section id="CD012040-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012040-list-0005"> <li> <p>Survival</p> <ol id="CD012040-list-0006"> <li> <p>Time to event (death or lung transplant)</p> </li> <li> <p>Mortality rate</p> </li> </ol> </li> <li> <p>Hospitalisation</p> <ol id="CD012040-list-0007"> <li> <p>Number of days</p> </li> <li> <p>Number of episodes</p> </li> <li> <p>Time to next hospitalisation</p> </li> </ol> </li> <li> <p>School or work attendance (i.e. number of days missed)</p> </li> <li> <p>Extra courses of antibiotics (measured as time to the next course of antibiotics and the total number of courses of antibiotics) </p> <ol id="CD012040-list-0008"> <li> <p>Oral</p> </li> <li> <p>Intravenous</p> </li> <li> <p>Inhaled</p> </li> </ol> </li> <li> <p>Pulmonary exacerbations (either physician‐ or protocol‐defined)</p> </li> <li> <p>Radiological measures of lung disease (assessed using any scoring system)</p> <ol id="CD012040-list-0009"> <li> <p>Chest radiograph score</p> </li> <li> <p>Computed tomography (CT) score</p> </li> </ol> </li> <li> <p>Acquisition of respiratory pathogens</p> <ol id="CD012040-list-0010"> <li> <p><i>Pseudomonas aeruginosa</i> </p> </li> <li> <p><i>Staphylococcus aureus</i> </p> </li> <li> <p><i>Haemophilus influenzae</i> </p> </li> <li> <p>Other significant pathogens</p> </li> </ol> </li> <li> <p>Eradication of respiratory pathogens (as defined by trial authors)</p> <ol id="CD012040-list-0011"> <li> <p><i>P aeruginosa</i> </p> </li> <li> <p><i>S aureus</i> </p> </li> <li> <p><i>H influenzae</i> </p> </li> <li> <p>Other significant pathogens</p> </li> </ol> </li> <li> <p>Nutrition and growth (measured as relative changes from baseline; including z scores or centiles) </p> <ol id="CD012040-list-0012"> <li> <p>Weight</p> </li> <li> <p>Body mass index (BMI)</p> </li> <li> <p>Height</p> </li> </ol> </li> <li> <p>Sweat chloride (change from baseline) as a measure of CFTR protein function in sweat glands </p> </li> <li> <p>Cost‐effectiveness (cost utility assessed as a comparison of impact on quality of adjusted life years) </p> </li> </ol> </p> </section> </section> </section> <section id="CD012040-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD012040-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register using the term 'drugs that correct stop codon mutations'. </p> <p>This register has been compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL; updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals: <i>Pediatric Pulmonology</i>  and  <i>Journal of Cystic Fibrosis</i>. We identified unpublished work by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference, the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. </p> <p>For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis and Genetic Disorders Group <a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>The date of the most recent search was 7 March 2022.</p> <p>We also searched the following databases and trial registries:</p> <p> <ol id="CD012040-list-0013"> <li> <p>US National Institutes of Health Ongoing Trials Register Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 4 October 2022); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>; searched 4 October 2022); </p> </li> <li> <p>European Union Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu</a>; searched 4 October 2022). </p> </li> </ol> </p> <p>For search strategies, please see the table in the appendices (<a href="./appendices#CD012040-sec-0105">Appendix 2</a>). </p> </section> <section id="CD012040-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and any relevant systematic reviews identified for further references to relevant trials. We also contacted the authors of included trials, leaders in the field and companies known to be developing and investigating therapies for PTC class I mutations to identify any trials that may have been missed by these searches. </p> </section> </section> <section id="CD012040-sec-0026"> <h3 class="title" id="CD012040-sec-0026">Data collection and analysis</h3> <section id="CD012040-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AA and Colin Higgins (CH)) independently assessed the suitability of each trial identified by the searches for the first version of this review. Two review authors (AA and IS) independently assessed their suitability for this review update. If any disagreement had arisen on the suitability of a trial for inclusion in the review, we would have attempted to reach a consensus by discussion, failing which, a third author (KS) would have arbitrated. </p> </section> <section id="CD012040-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (AA and CH for the first review; AA and IS for this review update) independently extracted relevant data from the included trials using a standardised data extraction form. If any disagreement had arisen on data extraction, we would have attempted to reach a consensus by discussion, failing which, a third author (KS) would have arbitrated. </p> <p>We intended to extract QoL scores ideally as relative changes from baseline, calculated as ((measurement at end of treatment ‐ measurement at baseline)/measurement at baseline) x 100. However, data were not reported for this analysis, and, instead, we extracted the absolute change from baseline. We extracted data for FEV<sub>1</sub> (relative change from baseline). The mean and standard error of the mean (SEM) for relative changes from baseline in FEV<sub>1</sub> and FVC were reported at 8, 16, 24, 32, 40 and 48 weeks through graphical representation (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>); two review authors (AA and CH) independently estimated these data. Regarding adverse events, we extracted data for severe adverse events (i.e. participants who required discontinuation of therapy). The Kerem trial report presented data for adverse events occurring in more than 10% of participants and the Konstan trial report presented data for adverse events occurring in 5% or more of participants; however, neither report provided information regarding whether treatment required interruption.  </p> <p>With regard to the secondary outcome, pulmonary exacerbations, we extracted the rate of pulmonary exacerbations and noted both protocol‐defined and physician‐defined rates. For the nutrition and growth outcome, the Kerem trial reported insufficient data for changes from baseline in each treatment arm. Instead, we extracted the difference in change in body weight and BMI between the ataluren and placebo arms. For total lung CT score and sweat chloride concentration, we extracted absolute changes from baseline. </p> <p>In future updates, if we include trials with different dosing regimens, we will combine the results of all dosing regimens together in a single analysis and subsequently undertake a subgroup analysis to assess the doses individually. We planned to report data as immediate (up to and including one month), medium term (over one month and up to six months) and long term (over six months). We extracted data for up to 48 weeks and estimates at 8, 16, 24, 32 and 40 weeks (when presented) for selected outcomes. Due to the limited data reported by the two included trials, we have only been able to combine data for some outcomes.  </p> </section> <section id="CD012040-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (AA and CH for the first review; AA and IS for this review update) independently assessed the risk of bias for the included trials using the Cochrane risk of bias tool (<a href="./references#CD012040-bbs2-0030" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). This included assessment of the following methodological aspects of the trials: </p> <p> <ol id="CD012040-list-0014"> <li> <p>procedure for randomisation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>masking (blinding) of the intervention from participants, clinicians and trial personnel evaluating outcomes (performance bias); </p> </li> <li> <p>missing outcome data (attrition bias);</p> </li> <li> <p>selective outcome reporting (reporting bias);</p> </li> <li> <p>other sources of bias (e.g. the influence of funding sources or industry on trial characteristics and presented results). </p> </li> </ol> </p> <p>We assessed whether all participants were included in an intention‐to‐treat (ITT) analysis, regardless of whether they completed the treatment schedule or not. If disagreement had arisen on the assessment of risk of bias, we would have attempted to reach a consensus by discussion, failing which, a third author (KS) would have arbitrated. </p> </section> <section id="CD012040-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we calculated the treatment effect for each outcome using the risk ratio (RR) and 95% confidence intervals (CIs). However (in a post hoc change), for the analysis of individual adverse events, we have used 99% CIs because the type I error rate (e.g. false positive) is greatly inflated with numerous tests. For continuous outcomes, we calculated the mean change from baseline and standard deviation (SD) for each group. We converted any reported SEMs to SDs. We calculated the mean difference (MD) and 95% CIs. One trial report did not state the number of participants for each time point for the 8‐weekly estimates of the relative change from baseline in FEV<sub>1</sub> (as well as the subgroup analysis by chronic inhaled tobramycin use for this outcome) and FVC (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). For these estimated data, because the withdrawal rate was 14% in the ataluren group and 11% in the placebo group, we felt it appropriate to use the respective ITT population for each treatment group and subgroup. For QoL, both studies used the CFQ‐R questionnaire, and we intended to calculate the MD and 95% CIs; however, the studies reported insufficient data. </p> <p>In the included trials, investigators analysed continuous outcomes over 48 weeks via a mixed‐model repeated‐measures analysis (MMRM) based on the average effect across all post‐baseline visits (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). Such an analysis is longitudinal and uses all available data at every visit. We have presented week 48 data for the relative change in FEV<sub>1</sub>, pulmonary exacerbation rate, total lung CT scores and change in sweat chloride concentration from the MMRM model for the effect at 48 weeks derived from the treatment, by visit term in the model (so data presented as 'up to 48 weeks' are the estimates from the model at the 48‐week time point). This also allows for covariate adjustment (baseline value, treatment, visit, treatment‐by‐visit interaction, baseline‐by‐visit interaction) and stratification (inhaled antibiotics (yes or no), baseline age (under 18 versus 18 years and over), and baseline per cent predicted FEV<sub>1</sub> (40% up to 65% versus 65% and up to 90%)). </p> <p>In future updates, if we identify any trials that report time‐to‐event outcomes, we will use measures of survival analysis and report hazard ratios and 95% CIs between different arms of the trial. Furthermore, if different trials do not report change data, but instead present absolute post‐treatment data without baseline data (so it is not possible to calculate change data), we will use absolute post‐treatment data instead of change from baseline. However, if the report presents baseline and post‐treatment data for any outcome, we will calculate SDs for the change from baseline (e.g. if the CI is available). When there is not enough information available to calculate the SDs for the changes, we aim to impute them from other trials in the review where the data are available and trials are similar (i.e. if the trials used the same measurement scale, had the same degree of measurement error and had the same time periods between baseline and measurement of the final value). If neither of these methods is possible, we will impute a change‐from‐baseline SD from another trial, making use of an imputed correlation coefficient following methods described in Chapter 23 in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD012040-bbs2-0031" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD012040-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Within this review, we only included results from RCTs of parallel design in which individual trial participants were randomised. We also reviewed cross‐over trials on an individual basis. However, we could not extract data from the first arm and, hence, we excluded them. We did not identify any cluster‐RCTs. In future updates, we will exclude cluster‐RCTs because this is not an appropriate study design for this type of intervention. </p> </section> <section id="CD012040-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>In order to allow an ITT analysis, we extracted data on the number of participants with each outcome event, by allocated treatment group, regardless of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow‐up. We recorded the number of participants with outcome data and checked whether this was consistent with the number of originally randomised participants. If any data were missing or unclear, we contacted the primary investigators for clarification. Specifically, we have contacted the authors of one excluded cross‐over trial on two occasions, asking whether data are available from the first arm of the trial and, if so, requesting that the investigators share these data with us (<a href="./references#CD012040-bbs2-0017" title="PradalU , CasottiV , DelmarcoA , NicolisE , LivraghiA , ConeseM , et al. Effects of gentamicin on ion transport, mRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology2002;34, Issue S24:263. [CENTRAL: 404061] [CFGD REGISTER: BD145] ">Pradal 2002</a>). To date, we have not received a response from the authors. However, if the first‐arm data from these trials are made available to us in the future, we will reassess this trial for inclusion. We also contacted the authors of a second cross‐over trial and were informed that the data are held by PTC Therapeutics (<a href="./references#CD012040-bbs2-0019" title="EUCTR2007-000724-40-BE. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007-000724-40-BE (first received 27 April 2007). [CFGD REGISTER: BD22e] NCT00458341. A study of ataluren in pediatric participants with cystic fibrosis [A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis]. clinicaltrials.gov/show/NCT00458341 (first received 10 April 2007). [CENTRAL: CN-02015168] [CFGD REGISTER: BD22d] Sermet-GaudelusI , BoeckKD , CasimirGJ , VermeulenF , LealT , MogenetA , et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;182(10):1262-72. [CENTRAL: 768705] [CFGD REGISTER: BD22c] Sermet-GaudelusI , De BoeckK , CasimirG , LealT , VermeulenF , MogenetA , et al. Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124. Pediatric Pulmonology2008;43(Suppl 31):313. [CENTRAL: 689497] [CFGD REGISTER: BD22b] Sermet-GaudelusI , LealT , De BoeckK , CasimirG , HanssensL , HageP , et al. PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis2008;7(Suppl 2):S22. [CENTRAL: 651984] [CFGD REGISTER: BD22a] ">Sermet‐Gaudelus 2010</a>). We did not receive a response to our request for the first‐arm data.  </p> </section> <section id="CD012040-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity through a visual examination of the combined data presented in the forest plots, and by considering the I<sup>2</sup> statistic (<a href="./references#CD012040-bbs2-0029" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), together with Chi<sup>2</sup> values and their CIs (<a href="./references#CD012040-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). This approach reflects the likelihood that variations in results across trials are due to heterogeneity rather than chance, and we interpreted the I<sup>2</sup> statistic using the following simple classification: </p> <p> <ol id="CD012040-list-0015"> <li> <p>0% to 40% might not be important;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100% may represent considerable heterogeneity.</p> </li> </ol> </p> </section> <section id="CD012040-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In order to identify selective outcome reporting, where possible we compared outcomes defined in the studies' protocols with those reported in their full publications. We explored the protocols of the included trials (found on the aforementioned clinical trials registries) for evidence of selective reporting bias. In future, if the protocol for an included trial is not available publicly, we will contact the primary investigators, corresponding author(s) or relevant pharmaceutical company for a copy. We also compared outcomes listed in the Methods section of the studies' final papers with those presented in the Results section. For negative findings that were reported either only partially or not at all, we contacted primary investigators for these data, which included: CFQ‐R score; weight; BMI; relative change in FVC; adverse events that led to interruption of treatment; grading classification of adverse events; hospitalisations; extra courses of antibiotics; and disruptions to school or work attendance. We did not receive any replies. </p> <p>We planned to assess publication bias by constructing and assessing the symmetry of a funnel plot. This would have been possible if we had included more than 10 trials in the review. </p> </section> <section id="CD012040-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model to analyse the data, regardless of the value of the I² statistic. </p> </section> <section id="CD012040-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to investigate any heterogeneity that we identified using subgroup analyses of potential confounding factors, if sufficient numbers (at least 10 trials) were available. For this review, we planned that these confounding factors would be: </p> <p> <ol id="CD012040-list-0016"> <li> <p>age (children (defined as younger than 18 years of age) versus adults);</p> </li> <li> <p>sex;</p> </li> <li> <p>intervention used.</p> </li> </ol> </p> <p>We did not plan any subgroup analyses by antibiotic use. However, one included trial presented a post hoc subgroup analysis by inhaled tobramycin use, which we have reported in the Results section below (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). Subsequently, a further trial was conducted that excluded participants who were using long‐term inhaled aminoglycosides within the preceding four months (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). This difference in participant baseline characteristics is also a potential confounding factor for future updates. </p> <p>The analysis in this review is based on aggregate data because we have no individual participant data. We will incorporate such analysis in future updates if these data are available. </p> </section> <section id="CD012040-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>If we had been able to combine a sufficient number of trials (at least 10), we planned to examine the impact of risk of bias on the results by comparing meta‐analyses including and excluding trials at high risk of selection or reporting bias, due to issues relating to randomisation, allocation concealment or masking of interventions from participants or trial personnel. </p> </section> <section id="CD012040-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We specified in our protocol that we would present three tables: the first for outcomes measured at up to one month; the second for outcomes measured between one and six months; and the third for longer‐term outcomes (over six months). We felt that data from previous trials, as well as reviews by <a href="./references#CD012040-bbs2-0038" title="SkiltonM , KrishanA , PatelS , SinhaIP , SouthernKW . Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD009841. [DOI: 10.1002/14651858.CD009841.pub3]">Skilton 2019</a> and <a href="./references#CD012040-bbs2-0039" title="SouthernKW , MurphyJ , SinhaIP , NevittSJ . Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD010966. [DOI: 10.1002/14651858.CD010966.pub3]">Southern 2020</a>, highlight the potential for a rapid response to this type of intervention and planned to present these in the first table. But we were also interested in illustrating evidence of a sustained response in the short to medium term, because we feel this is important for stakeholders. Thus, we aimed to present such data in the second table. At present, data for short‐ and medium‐term outcomes are not available; therefore, we have presented a summary of findings table for longer‐term outcomes (<a href="./full#CD012040-tbl-0001">summary of findings Table 1</a>). </p> <p>As planned, we have presented the following outcomes in the summary of findings table: QoL, respiratory function measures (FEV<sub>1</sub>), adverse events, pulmonary exacerbations, nutrition and growth, and sweat chloride level. In a post hoc change, we have also added the outcome of mortality. </p> <p>We determined the certainty of the evidence using the GRADE approach, and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results and a high probability of publication bias. We downgraded the evidence by one level if we considered the limitation to be serious and by two levels if we considered it to be very serious. Under the GRADE approach, evidence can be upgraded if a large treatment effect is demonstrated with no obvious biases, or if a dose–response effect exists. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012040-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012040-sec-0039"></div> <section id="CD012040-sec-0040"> <h3 class="title">Description of studies</h3> <p>Descriptions of the included and excluded studies are provided in the <a href="./references#CD012040-sec-0115" title="">Characteristics of included studies</a> and <a href="./references#CD012040-sec-0116" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD012040-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search of the Group's Cystic Fibrosis Trials Register identified 44 publications (abstracts and full papers) representing seven trials. The search of the online clinical trials registries identified 13 trials with a single reference each (<a href="./references#CD012040-bbs2-0014" title="NCT03670472. Optimization of correcting molecules of nonsense mutations in epithelial cells of the upper airways of patients with cystic fibrosis with nonsense mutations in the CFTR gene. clinicaltrials.gov/ct2/show/NCT03670472 (first received 13 September 2018). ">NCT03670472</a>; <a href="./references#CD012040-bbs2-0015" title="NCT04126473. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04126473 (first received 15 October 2019). ">NCT04126473</a>; <a href="./references#CD012040-bbs2-0006" title="NCT00351078. A phase 2b extension study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00351078 (first received 12 July 2006). ">NCT00351078</a>; <a href="./references#CD012040-bbs2-0011" title="NCT03256799. An open label study to investigate the role of ivacaftor for the treatment of cystic fibrosis in combination with ataluren (PTC124) in cystic fibrosis patients using ataluren for nonsense mutations. clinicaltrials.gov/ct2/show/NCT03256799 (first received 19 July 2019). ">NCT03256799</a>; <a href="./references#CD012040-bbs2-0012" title="NCT03256968. An open label N of 1 study to evaluate the study and efficacy of long-term treatment with ivacaftor in combination with ataluren (PTC124) in subjects with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03256968 (first received 26 March 2020). ">NCT03256968</a>; <a href="./references#CD012040-bbs2-0007" title="NCT00376428. Application of functional electrophysiological tests to evaluate pharmacological treatments in patients with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00376428 (first received 14 September 2006). ">NCT00376428</a>; <a href="./references#CD012040-bbs2-0013" title="NCT03624101. Novel therapeutic approaches for treatment of CF patients with W1282X premature termination codon mutations. clinicaltrials.gov/ct2/show/NCT03624101 (first received 9 August 2019). ">NCT03624101</a>; <a href="./references#CD012040-bbs2-0016" title="NCT04135495. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04135495 (first received 22 October 2019). ">NCT04135495</a>; <a href="./references#CD012040-bbs2-0006" title="NCT00351078. A phase 2b extension study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00351078 (first received 12 July 2006). ">NCT00351078</a>; <a href="./references#CD012040-bbs2-0011" title="NCT03256799. An open label study to investigate the role of ivacaftor for the treatment of cystic fibrosis in combination with ataluren (PTC124) in cystic fibrosis patients using ataluren for nonsense mutations. clinicaltrials.gov/ct2/show/NCT03256799 (first received 19 July 2019). ">NCT03256799</a>; <a href="./references#CD012040-bbs2-0012" title="NCT03256968. An open label N of 1 study to evaluate the study and efficacy of long-term treatment with ivacaftor in combination with ataluren (PTC124) in subjects with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03256968 (first received 26 March 2020). ">NCT03256968</a>; <a href="./references#CD012040-bbs2-0014" title="NCT03670472. Optimization of correcting molecules of nonsense mutations in epithelial cells of the upper airways of patients with cystic fibrosis with nonsense mutations in the CFTR gene. clinicaltrials.gov/ct2/show/NCT03670472 (first received 13 September 2018). ">NCT03670472</a>; <a href="./references#CD012040-bbs2-0015" title="NCT04126473. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04126473 (first received 15 October 2019). ">NCT04126473</a>), as well as four additional references to trials found through the initial search of the Group’s register. We did not identify any additional trials by screening references of included trials or by contacting the authors of included trials, leaders in the field or companies known to be developing and investigating ataluren and similar compounds. </p> <p>We included two trials (28 references) (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>), and excluded 18 trials (28 references) (<a href="./references#CD012040-bbs2-0003" title="KeremE , HirawatS , ArmoniS , YaakovY , ShoseyovD , CohenM , et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet2008;372:719-27. KeremE , YaakovY , ArmoniS , PugatschT , ShoseyovD , CohenM , et al. PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis. Pediatric Pulmonology2008;43(Suppl 31):294. [CENTRAL: 691199] [CFGD REGISTER: BD203b] WilschanskiM , ArmoniS , YaakovY , BlauH , ShoseyovD , CohenM , et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis2008;7(Suppl 2):S22. [CENTRAL: 651985] [CFGD REGISTER: BD203a] WilschanskiM , MillerLL , ShoseyovD , BlauH , RivlinJ , AviramM , et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal2011;38:59-69. ">Kerem 2008</a>; <a href="./references#CD012040-bbs2-0004" title="NCT00234663. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00234663 (first received 7 October 2005). ">NCT00234663</a>; <a href="./references#CD012040-bbs2-0005" title="NCT00237380. Safety and efficacy of ataluren (PTC124) for cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00237380 (first received 12 October 2005). ">NCT00237380</a>; <a href="./references#CD012040-bbs2-0006" title="NCT00351078. A phase 2b extension study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00351078 (first received 12 July 2006). ">NCT00351078</a>; <a href="./references#CD012040-bbs2-0007" title="NCT00376428. Application of functional electrophysiological tests to evaluate pharmacological treatments in patients with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00376428 (first received 14 September 2006). ">NCT00376428</a>; <a href="./references#CD012040-bbs2-0008" title="NCT01140451. A phase 3 extension study of ataluren (PTC124®) in subjects with nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01140451 (first received 19 October 2020). ">NCT01140451</a>; <a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>; <a href="./references#CD012040-bbs2-0010" title="NCT02456103. Extension study of ataluren in participants with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02456103 (first received 15 April 2020). ">NCT02456103</a>; <a href="./references#CD012040-bbs2-0011" title="NCT03256799. An open label study to investigate the role of ivacaftor for the treatment of cystic fibrosis in combination with ataluren (PTC124) in cystic fibrosis patients using ataluren for nonsense mutations. clinicaltrials.gov/ct2/show/NCT03256799 (first received 19 July 2019). ">NCT03256799</a>; <a href="./references#CD012040-bbs2-0012" title="NCT03256968. An open label N of 1 study to evaluate the study and efficacy of long-term treatment with ivacaftor in combination with ataluren (PTC124) in subjects with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03256968 (first received 26 March 2020). ">NCT03256968</a>; <a href="./references#CD012040-bbs2-0013" title="NCT03624101. Novel therapeutic approaches for treatment of CF patients with W1282X premature termination codon mutations. clinicaltrials.gov/ct2/show/NCT03624101 (first received 9 August 2019). ">NCT03624101</a>; <a href="./references#CD012040-bbs2-0014" title="NCT03670472. Optimization of correcting molecules of nonsense mutations in epithelial cells of the upper airways of patients with cystic fibrosis with nonsense mutations in the CFTR gene. clinicaltrials.gov/ct2/show/NCT03670472 (first received 13 September 2018). ">NCT03670472</a>; <a href="./references#CD012040-bbs2-0015" title="NCT04126473. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04126473 (first received 15 October 2019). ">NCT04126473</a>; <a href="./references#CD012040-bbs2-0016" title="NCT04135495. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04135495 (first received 22 October 2019). ">NCT04135495</a>; <a href="./references#CD012040-bbs2-0017" title="PradalU , CasottiV , DelmarcoA , NicolisE , LivraghiA , ConeseM , et al. Effects of gentamicin on ion transport, mRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology2002;34, Issue S24:263. [CENTRAL: 404061] [CFGD REGISTER: BD145] ">Pradal 2002</a>; <a href="./references#CD012040-bbs2-0018" title="RomanoL , CasciaroR , VaniniP , Zegarra-MoranO , NegroI , MinutoN , et al. Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations. In: 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:11. [CENTRAL: 354451] [CFGD REGISTER: BD144b] RomanoL , SacchiR , Zegarra-MoranO , VaniniP , GuerrieroF , CasciaroR , et al. Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations. Pediatric Pulmonology2000;30, Issue S20:250. [CENTRAL: 315387] [CFGD REGISTER: BD144a] ">Romano 2000</a>; <a href="./references#CD012040-bbs2-0019" title="EUCTR2007-000724-40-BE. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007-000724-40-BE (first received 27 April 2007). [CFGD REGISTER: BD22e] NCT00458341. A study of ataluren in pediatric participants with cystic fibrosis [A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis]. clinicaltrials.gov/show/NCT00458341 (first received 10 April 2007). [CENTRAL: CN-02015168] [CFGD REGISTER: BD22d] Sermet-GaudelusI , BoeckKD , CasimirGJ , VermeulenF , LealT , MogenetA , et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;182(10):1262-72. [CENTRAL: 768705] [CFGD REGISTER: BD22c] Sermet-GaudelusI , De BoeckK , CasimirG , LealT , VermeulenF , MogenetA , et al. Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124. Pediatric Pulmonology2008;43(Suppl 31):313. [CENTRAL: 689497] [CFGD REGISTER: BD22b] Sermet-GaudelusI , LealT , De BoeckK , CasimirG , HanssensL , HageP , et al. PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis2008;7(Suppl 2):S22. [CENTRAL: 651984] [CFGD REGISTER: BD22a] ">Sermet‐Gaudelus 2010</a>; <a href="./references#CD012040-bbs2-0020" title="WilschanskiM , VirgilisD , Strauss-LiviatanN , TalA , BenturL , BlauH , et al. Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: A double-blind placebo controlled trial. Pediatric Pulmonology2000;30, Issue S20:244. [CENTRAL: 315400] [CFGD REGISTER: BD143a] WilschanskiM , YahavJ , BlauH , BenturL , RivlinJ , AviramM , et al. Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: A double blind placebo controlled trial. Gastroenterology2003;124(4 Suppl 1):A582. [CENTRAL: 643127] [CFGD REGISTER: BD143c] WilschanskiM , YahavY , YaacovY , BlauH , BenturL , RivlinJ , et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine2003;349(15):1433-41. [CENTRAL: 440623] [CFGD REGISTER: BD143b] [PMID: 14534336]">Wilschanski 2003b</a>). No trials are listed as ongoing or awaiting classification. The results of the search are shown in the PRISMA diagram (<a href="#CD012040-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012040-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD012040-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> </section> <section id="CD012040-sec-0042"> <h4 class="title">Included studies</h4> <p> We included two trials (28 references) with 517 participants in total; both trials were available as full‐text articles (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> <section id="CD012040-sec-0043"> <h5 class="title">Trial design</h5> <p>Both trials were RCTs of parallel design with two arms, and PTC Therapeutics Incorporated was the responsible funding body. The Cystic Fibrosis Foundation collaborated with both trials. The US Food and Drug Administration's Office of Orphan Products Development and the US National Institutes of Health were also involved in providing grant support to one trial (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> <p>Both trials were phase III trials, each lasting 48 weeks. Participants in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study who completed 48 weeks of treatment were entered into an ongoing open‐label extension phase that is planned to last up to 96 weeks (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). Participants from this extension trial are not eligible for inclusion in this review because they were not re‐randomised to treatment or control. </p> <p>The included trials were conducted at multiple centres internationally. The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study recruited participants from 36 sites in 11 countries in North America and Europe, and reported outcome data at time frames ranging from eight to 48 weeks. The <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> study recruited participants from 75 sites in 16 countries in North America, South America, Europe and Israel, and reported outcome data at 48 weeks (although the trial registry entry states 88 sites). </p> </section> <section id="CD012040-sec-0044"> <h5 class="title">Participants</h5> <p>All 517 participants (270 male, 247 female) had a confirmed diagnosis of CF with documentation of the presence of a nonsense mutation in at least one allele of the <i>CFTR</i> gene. The trials recruited participants aged six years and over; the mean age was 23 years in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study and 22 years in the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> study. Participants were allocated in a 1:1 ratio to either intervention or placebo. Participants were stratified according to age (under 18 years versus 18 years and over), chronic inhaled antibiotic use (yes versus no) and FEV<sub>1</sub>% predicted (40% up to 65% versus 65% up to 90%). The <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial only recruited participants not receiving chronic inhaled aminoglycosides. All participants had a baseline FEV<sub>1</sub> of 40% or over for age, sex and height. Where baseline characteristics were presented, they were similar in the intervention and the placebo arms, with no statistically significant differences between the two arms (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>).  </p> </section> <section id="CD012040-sec-0045"> <h5 class="title">Interventions</h5> <p>The intervention drug used in both included trials was ataluren (administered as a powdered oral suspension). The trials compared a three‐times daily regimen of ataluren (10 mg/kg in the morning, 10 mg/kg at midday and 20 mg/kg in the evening) to placebo. Participants continued on prescribed medications that were approved for CF during the trial period (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0046"> <h5 class="title">Outcomes</h5> <p>The primary endpoints for both trials was change in FEV<sub>1</sub> % predicted from baseline to week 48, assessed by spirometry. The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study reported relative change and the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> study reported absolute change in FEV<sub>1</sub> % predicted as the primary endpoint. Both trials used the CFQ‐R respiratory domain to measure QoL (<a href="./references#CD012040-bbs2-0037" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8. [DOI: 10.1378/chest.08-1190]">Quittner 2009</a>). The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study reported on the mean change in the score from baseline to week 48 in the supplementary text. Both trials reported on the safety profile of ataluren. The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study reported on the pulmonary exacerbation rate using the modified Fuchs' definition, whereas the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> study reported on this using the expanded Fuchs' definition. Both trials reported on the change from baseline for BMI, and the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study also reported on difference between groups for the change in body weight. </p> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study reported on changes in total lung CT scores and subscores. This trial also reported the absolute difference in change in sweat chloride concentration from baseline between the two treatment arms. The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study also reported nasal potential difference, a tertiary endpoint. We did not include it in this review as it is not yet a validated outcome. </p> </section> </section> <section id="CD012040-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded 18 trials (28 references) (see <a href="./references#CD012040-sec-0116" title="">Characteristics of excluded studies</a>). </p> <p>One trial was of cross‐over design, and we could not extract data from just the first treatment arm (<a href="./references#CD012040-bbs2-0017" title="PradalU , CasottiV , DelmarcoA , NicolisE , LivraghiA , ConeseM , et al. Effects of gentamicin on ion transport, mRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology2002;34, Issue S24:263. [CENTRAL: 404061] [CFGD REGISTER: BD145] ">Pradal 2002</a>). We contacted the investigators of this trial requesting the relevant data, but the data have not been made available to us. We excluded one trial because it reported on the mechanism of action of the intervention and not on the clinical benefit (<a href="./references#CD012040-bbs2-0020" title="WilschanskiM , VirgilisD , Strauss-LiviatanN , TalA , BenturL , BlauH , et al. Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: A double-blind placebo controlled trial. Pediatric Pulmonology2000;30, Issue S20:244. [CENTRAL: 315400] [CFGD REGISTER: BD143a] WilschanskiM , YahavJ , BlauH , BenturL , RivlinJ , AviramM , et al. Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: A double blind placebo controlled trial. Gastroenterology2003;124(4 Suppl 1):A582. [CENTRAL: 643127] [CFGD REGISTER: BD143c] WilschanskiM , YahavY , YaacovY , BlauH , BenturL , RivlinJ , et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine2003;349(15):1433-41. [CENTRAL: 440623] [CFGD REGISTER: BD143b] [PMID: 14534336]">Wilschanski 2003b</a>). A phase II trial did not randomise participants to treatment and entered participants into an open‐label extension trial where, again, participants were not randomised to control or treatment (<a href="./references#CD012040-bbs2-0003" title="KeremE , HirawatS , ArmoniS , YaakovY , ShoseyovD , CohenM , et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet2008;372:719-27. KeremE , YaakovY , ArmoniS , PugatschT , ShoseyovD , CohenM , et al. PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis. Pediatric Pulmonology2008;43(Suppl 31):294. [CENTRAL: 691199] [CFGD REGISTER: BD203b] WilschanskiM , ArmoniS , YaakovY , BlauH , ShoseyovD , CohenM , et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis2008;7(Suppl 2):S22. [CENTRAL: 651985] [CFGD REGISTER: BD203a] WilschanskiM , MillerLL , ShoseyovD , BlauH , RivlinJ , AviramM , et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal2011;38:59-69. ">Kerem 2008</a>). Another trial did not randomise participants to treatment and used participants homozygous for deltaF508 mutations as the control group, which was inappropriate for inclusion in this review (<a href="./references#CD012040-bbs2-0018" title="RomanoL , CasciaroR , VaniniP , Zegarra-MoranO , NegroI , MinutoN , et al. Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations. In: 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:11. [CENTRAL: 354451] [CFGD REGISTER: BD144b] RomanoL , SacchiR , Zegarra-MoranO , VaniniP , GuerrieroF , CasciaroR , et al. Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations. Pediatric Pulmonology2000;30, Issue S20:250. [CENTRAL: 315387] [CFGD REGISTER: BD144a] ">Romano 2000</a>). We excluded an open‐label extension of the included <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial, where participants have not been re‐randomised and all participants are receiving the same treatment (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). Seven trials did not randomise and participants were allocated to a single treatment (<a href="./references#CD012040-bbs2-0007" title="NCT00376428. Application of functional electrophysiological tests to evaluate pharmacological treatments in patients with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00376428 (first received 14 September 2006). ">NCT00376428</a>; <a href="./references#CD012040-bbs2-0008" title="NCT01140451. A phase 3 extension study of ataluren (PTC124®) in subjects with nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01140451 (first received 19 October 2020). ">NCT01140451</a>; <a href="./references#CD012040-bbs2-0010" title="NCT02456103. Extension study of ataluren in participants with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02456103 (first received 15 April 2020). ">NCT02456103</a>; <a href="./references#CD012040-bbs2-0011" title="NCT03256799. An open label study to investigate the role of ivacaftor for the treatment of cystic fibrosis in combination with ataluren (PTC124) in cystic fibrosis patients using ataluren for nonsense mutations. clinicaltrials.gov/ct2/show/NCT03256799 (first received 19 July 2019). ">NCT03256799</a>; <a href="./references#CD012040-bbs2-0012" title="NCT03256968. An open label N of 1 study to evaluate the study and efficacy of long-term treatment with ivacaftor in combination with ataluren (PTC124) in subjects with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03256968 (first received 26 March 2020). ">NCT03256968</a>; <a href="./references#CD012040-bbs2-0013" title="NCT03624101. Novel therapeutic approaches for treatment of CF patients with W1282X premature termination codon mutations. clinicaltrials.gov/ct2/show/NCT03624101 (first received 9 August 2019). ">NCT03624101</a>; <a href="./references#CD012040-bbs2-0015" title="NCT04126473. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04126473 (first received 15 October 2019). ">NCT04126473</a>). One non‐randomised trial assessed dose escalation (<a href="./references#CD012040-bbs2-0016" title="NCT04135495. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04135495 (first received 22 October 2019). ">NCT04135495</a>), whereas a further three cross‐over trials were excluded because they compared dosing regimens and were not placebo‐controlled (<a href="./references#CD012040-bbs2-0004" title="NCT00234663. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00234663 (first received 7 October 2005). ">NCT00234663</a>; <a href="./references#CD012040-bbs2-0005" title="NCT00237380. Safety and efficacy of ataluren (PTC124) for cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00237380 (first received 12 October 2005). ">NCT00237380</a>; <a href="./references#CD012040-bbs2-0019" title="EUCTR2007-000724-40-BE. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007-000724-40-BE (first received 27 April 2007). [CFGD REGISTER: BD22e] NCT00458341. A study of ataluren in pediatric participants with cystic fibrosis [A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis]. clinicaltrials.gov/show/NCT00458341 (first received 10 April 2007). [CENTRAL: CN-02015168] [CFGD REGISTER: BD22d] Sermet-GaudelusI , BoeckKD , CasimirGJ , VermeulenF , LealT , MogenetA , et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;182(10):1262-72. [CENTRAL: 768705] [CFGD REGISTER: BD22c] Sermet-GaudelusI , De BoeckK , CasimirG , LealT , VermeulenF , MogenetA , et al. Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124. Pediatric Pulmonology2008;43(Suppl 31):313. [CENTRAL: 689497] [CFGD REGISTER: BD22b] Sermet-GaudelusI , LealT , De BoeckK , CasimirG , HanssensL , HageP , et al. PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis2008;7(Suppl 2):S22. [CENTRAL: 651984] [CFGD REGISTER: BD22a] ">Sermet‐Gaudelus 2010</a>). One of these trials also entered participants into an open‐label extension trial that was excluded (<a href="./references#CD012040-bbs2-0006" title="NCT00351078. A phase 2b extension study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00351078 (first received 12 July 2006). ">NCT00351078</a>). One trial was excluded because it was a laboratory‐based case‐control study (<a href="./references#CD012040-bbs2-0014" title="NCT03670472. Optimization of correcting molecules of nonsense mutations in epithelial cells of the upper airways of patients with cystic fibrosis with nonsense mutations in the CFTR gene. clinicaltrials.gov/ct2/show/NCT03670472 (first received 13 September 2018). ">NCT03670472</a>). </p> </section> </section> <section id="CD012040-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>We present a graphical summary of the risk of bias assessments for the included trials in <a href="#CD012040-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012040-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012040-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012040-sec-0049"> <h4 class="title">Allocation</h4> <section id="CD012040-sec-0050"> <h5 class="title">Sequence generation</h5> <p>Both included trials reported that the randomisation code was externally generated using a small block size, stratified by age (under 18 years versus 18 years and over), chronic inhaled antibiotic use (yes versus no), and FEV<sub>1</sub> % predicted (40% up to 65% versus 65% up to 90%). We judged the trials to have a low risk of bias for sequence generation (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0051"> <h5 class="title">Allocation concealment</h5> <p>Participants in both the included trials were allocated to ataluren or placebo using interactive response technology according to the concealed randomisation list, and we judged the risk of bias for allocation concealment to be low (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> </section> <section id="CD012040-sec-0052"> <h4 class="title">Blinding</h4> <p>The trials stated that participants were blinded to treatment assignment and that the placebo was identical in appearance to the active drug. Although neither trial referred to the consistency or taste of the orally administered powder for suspension, we judge both trials to have a low risk of bias with regard to the blinding of participants (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>).  </p> <p>Both trials reported on blinding of trial personnel to treatment assignments, including medical and ancillary staff, the trial investigators and the sponsor (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). The trials specifically stated that only designated personnel at the contract research organisation had access to the treatment assignments; therefore, we judged the trials to have a low risk of bias with regard to the blinding of personnel.  </p> </section> <section id="CD012040-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition was low for both trials (less than 15%). In the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study, there were 116 participants in the ITT population in each treatment arm. In the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> study, there were 138 participants in the ataluren arm and 136 in the placebo arm included in the ITT analysis. We judged there to be a low risk of bias from incomplete outcome data for both trials (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> <p>In the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial, 20 participants from the ataluren group and 14 participants from the placebo group withdrew from the trial (P = 0.36). Six participants were excluded prior to week eight because they did not have valid post‐baseline spirometry: four from the ataluren group and two from the placebo group. These participants were not included in the ITT population. After week eight, 16 participants from the ataluren group withdrew from the trial. The reasons for exclusion for discontinuation for all participants (ataluren n = 120; placebo =  116) are as follows. Twenty participants in total withdrew from the ataluren group: seven due to an adverse event; one who was lost to follow‐up; nine who withdrew consent; one because of investigator decision; one due to protocol non‐compliance; and one who withdrew for 'other' reasons. Fourteen participants in total withdrew from the placebo group: two due to an adverse event; nine who withdrew consent; one due to protocol non‐compliance; and two for 'other' reasons. The investigators reported the following missing values in % predicted FEV<sub>1</sub> "12% (104/840) in the ataluren treatment group and 9% (73/820) in the placebo group" (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). We identified the following missing data from the ataluren group: one participant's total lung CT score at week 48 and three participants' change from baseline in sweat chloride concentration. In the placebo group, the investigators reported that week 48 FEV<sub>1</sub> data were missing for one participant and that this participant was excluded from the per‐protocol population analysis; in addition, we found that data for seven participants for the change from baseline in sweat chloride concentration were missing. </p> <p>In the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> study, 14 participants from the ataluren group and 13 from the placebo group withdrew from the trial (P = 0.82). Of these withdrawals, five participants (two from the ataluren group and three from the placebo group) were excluded prior to week eight because they did not have valid post‐baseline spirometry. These participants were not included in the ITT population. A further 11 participants in each group were withdrawn from the trial after week eight, but reasons were not provided. The investigators reported missing FEV<sub>1</sub> data at 48 weeks for 15 participants in the ataluren group and 21 participants in the placebo group (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>).  </p> </section> <section id="CD012040-sec-0054"> <h4 class="title">Selective reporting</h4> <p>The protocols for the included trials were found through online clinical trials registries (<a href="https://clinicaltrials.gov/ct2/show/NCT00803205" target="_blank">NCT00803205</a>; <a href="https://clinicaltrials.gov/ct2/show/NCT02139306" target="_blank">NCT02139306</a>). The following outcomes were included in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> protocol, but not reported in the full publication: ataluren (PTC124) pharmacokinetics; antibiotic use and hospitalisation due to CF‐related symptoms; and disruptions to school or work due to CF‐related symptoms. For QoL, weight and BMI, the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported no significant difference in mean change from baseline between treatment arms, but did not state either baseline and week 48 data or the change from baseline in each group to allow further analysis. Regarding adverse events, the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported adverse events that occurred in more than 10% of the population and the adverse events that led to discontinuation of treatment. The trial did not report whether an adverse event led to the interruption of treatment (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). By not reporting the aforementioned information, the trial is at high risk of selective outcome reporting. </p> <p>In the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial, investigators undertook a post hoc subgroup analysis of participants depending on their use of chronic inhaled antibiotics; however, they only reported findings for selected outcomes in that subgroup (relative change from baseline in FEV<sub>1</sub>, absolute values for FEV<sub>1</sub>, pulmonary exacerbation rate and total lung CT scores). The investigators selectively reported data for participants who were or were not receiving inhaled tobramycin, and did not report data for other inhaled antibiotics. Absolute values for FEV<sub>1</sub> at baseline and week 48 were presented for the subgroup of participants who were not receiving chronic inhaled tobramycin, highlighting favourable results for ataluren in this particular group of participants. The trial did not report complete data to allow analysis (i.e. baseline/week 48/change from baseline) of non‐significant outcomes, including total lung CT scores by subgroup and relative change from baseline in FEV<sub>1</sub> in participants on long‐term inhaled tobramycin, and instead stated that there was no significant difference between treatment arms (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). Due to selectively reporting the findings of the subgroup of participants who were not receiving chronic inhaled tobramycin, we judge the trial to be at high risk of reporting bias. </p> <p>The <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial reported on all the protocol outcomes in either the main paper or online. The trial reported on treatment‐emergent adverse events occurring in more than 5% of the population and adverse events that led to discontinuation of treatment. The trial did not report whether an adverse event led to the interruption of treatment (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). We therefore judge the trial to be at low risk of bias. </p> </section> <section id="CD012040-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>The baseline characteristics of participants in the treatment arms were similar in both trials. The median rate of compliance was based on trial drug accountability and was reported to be approximately 90% for ataluren and approximately 85% for placebo in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial, and 96% for ataluren and 95% for placebo in the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial. </p> <p><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> undertook a post hoc subgroup analysis of participants by chronic inhaled antibiotic use. This was not a subgroup that we planned to report on, but we have presented the results directly from the paper within our results below. The rationale for doing this analysis in the trial is not entirely clear; the investigators hypothesised that aminoglycosides, including inhaled tobramycin, interfere with ataluren at a ribosomal level. A post hoc in vitro trial demonstrated that aminoglycosides (tobramycin or gentamicin) reduce ataluren's ability to read through the PTC, and that this effect was not seen with the other tested inhaled antibiotics, colistin or aztreonam (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). There is no further scientific evidence for such an effect. The <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial was specifically designed with these results in mind and excluded participants receiving chronic inhaled or systemic tobramycin within four weeks prior to screening. </p> </section> </section> <section id="CD012040-sec-0056"> <h3 class="title" id="CD012040-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD012040-tbl-0001"><b>Summary of findings 1</b> Ataluren versus placebo for people with cystic fibrosis with class I mutations (PTCs)</a> </p> <p>Both of our included studies compared ataluren to placebo (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). We have graded the certainty of the evidence of those outcomes included in the summary of findings tables. For the definitions of these gradings, please refer to <a href="./full#CD012040-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012040-sec-0057"> <h4 class="title">Primary outcomes</h4> <section id="CD012040-sec-0058"> <h5 class="title">1. Quality of life</h5> <section id="CD012040-sec-0059"> <h6 class="title">a. Total QoL score</h6> <p>Neither trial reported on total QoL scores.</p> </section> <section id="CD012040-sec-0060"> <h6 class="title">b. Different subdomains</h6> <p>Both trials reported on the CFQ‐R respiratory domain scores, but only one provided data we could analyse (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> <p><a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported the change from baseline in CFQ‐R respiratory domain scores. There was no statistically significant difference in the mean change from baseline between the two groups at week 48 (MD 0.27, 95% CI ‐3.55 to 4.10; P = 0.89; 1 trial, 274 participants; <a href="./references#CD012040-fig-0003" title="">Analysis 1.1</a>). </p> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial did not report absolute data at baseline and week 48; however, it did report on the mean change in CFQ‐R respiratory domain scores from baseline to week 48. The reported difference in the mean changes between ataluren and placebo was 2.9 for the age group 6 to 13 years and 0.5 for participants aged 14 and over, neither of which were statistically significant (P = 0.8152 and P = 0.3723, respectively). We were unable to conduct analyses due to the insufficient data provided (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> </section> </section> <section id="CD012040-sec-0061"> <h5 class="title">2. Respiratory function measures (litres or per cent (%) predicted)</h5> <section id="CD012040-sec-0062"> <h6 class="title">a. FEV<sub>1</sub> (relative change from baseline) </h6> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study reported the relative change from baseline in FEV<sub>1</sub> % predicted at up to 48 weeks and presented data in graphical format at 8‐weekly intervals (i.e. at 8, 16, 24, 32 and 40 weeks). At up to 48 weeks, both treatment arms showed a decline in mean relative change from baseline in FEV<sub>1</sub> % predicted, but there was no difference between groups (MD 2.97%, 95% CI ‐0.58 to 6.52; P = 0.10; 1 trial, 203 participants; <a href="./references#CD012040-fig-0004" title="">Analysis 1.2</a>). Using data deduced from the graph (figure 2 in the full paper; <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>), at 8 weeks, we found a benefit with ataluren versus placebo (estimated MD 3.50%, 95% CI 0.86 to 6.14; P = 0.009; 1 trial, 232 participants; <a href="./references#CD012040-fig-0004" title="">Analysis 1.2</a>). At the remaining time points, the results demonstrated no difference between treatment groups (<a href="./references#CD012040-fig-0004" title="">Analysis 1.2</a>). </p> <section id="CD012040-sec-0063"> <p><b>Subgroup analysis</b></p> <p>In a post hoc subgroup analysis of participants by chronic inhaled antibiotic use, <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported that, at up to 48 weeks, the subgroup of participants who did not receive chronic inhaled tobramycin experienced a greater mean relative decline from baseline in FEV<sub>1</sub> % predicted in the placebo arm (MD 5.70%, 95% CI 1.71 to 9.69; P = 0.005; 1 trial, 146 participants; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>). In addition, <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> showed an estimated benefit with ataluren versus placebo at eight weeks (MD 5.70%, 95% CI 2.21 to 9.19; P = 0.001; 1 trial, 146 participants; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>), at 32 weeks (MD 5.40%, 95% CI 1.08 to 9.72; P = 0.01; 1 trial, 146 participants; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>) and at 40 weeks (MD 4.00%, 95% CI 0.03 to 7.97; P = 0.05; 1 trial, 146 participants; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>). However, there was no treatment difference at week 16 (MD 1.40%, 95% CI ‐1.94 to 4.74; P = 0.41; 1 trial, 146 participants; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>) and week 24 (MD 1.80%, 95% CI ‐2.52 to 6.12; P = 0.41; 1 trial, 146 participants; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>) (data estimated from figure 3 in full paper; <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> <p>In the subgroup of participants who were receiving chronic inhaled tobramycin, <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported no difference at up to 48 weeks (MD ‐1.60%, 95% CI ‐8.15 to 4.95; P = 0.63; 1 trial, 86 participants; <a href="./references#CD012040-fig-0006" title="">Analysis 1.4</a>). There was an estimated difference at 24 weeks in the same subgroup of participants that favoured placebo (MD ‐6.80%, 95% CI ‐12.35 to ‐1.25; P = 0.02; 1 trial, 86 participants; <a href="./references#CD012040-fig-0006" title="">Analysis 1.4</a>), but no estimated treatment difference at each of the other 8‐weekly time points in this subgroup (<a href="./references#CD012040-fig-0006" title="">Analysis 1.4</a>) (data estimated from figure 3 in full paper; <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> </section> </section> <section id="CD012040-sec-0064"> <h6 class="title">b. FEV<sub>1</sub> absolute values </h6> <p>Both trials reported absolute values for FEV<sub>1</sub> % predicted: <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported values at baseline and at week 48 and <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported the absolute mean change from baseline. <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported no difference in absolute baseline FEV<sub>1</sub> % predicted between the ataluren and placebo groups and no difference in the mean change from baseline at week 48 between the treatment groups (MD 1.76%, 95% CI ‐0.43 to 3.95; P = 0.12; 1 trial, 203 participants; <a href="./references#CD012040-fig-0007" title="">Analysis 1.5</a>). </p> <section id="CD012040-sec-0065"> <p><b>Subgroup analysis</b></p> <p>In the subgroup analysis of participants not receiving chronic inhaled tobramycin, <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> identified a lesser decline in mean absolute change in FEV<sub>1</sub> in the ataluren group compared with the placebo group (MD 3.40%, 95% CI 0.75 to 6.05; <a href="./references#CD012040-fig-0008" title="">Analysis 1.6</a>) in 125 participants not taking chronic inhaled tobramycin (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). No data for mean absolute change in FEV<sub>1</sub> % predicted were reported for participants who were receiving long‐term inhaled tobramycin. </p> <p><a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> only recruited participants who were not receiving chronic inhaled aminoglycosides, and found no difference between groups (n = 274) in the absolute mean change in FEV<sub>1</sub> % predicted (MD 0.59%, 95% CI ‐1.33 to 2.51; <a href="./references#CD012040-fig-0008" title="">Analysis 1.6</a>). </p> <p>Combined data at 48 weeks for absolute mean change in FEV<sub>1</sub> % predicted in participants not receiving chronic inhaled aminoglycosides demonstrated no difference between groups (MD 1.84%, 95% CI ‐0.90 to 4.58; P = 0.19, I<sup>2</sup> = 65%; 2 trials, 399 participants; <a href="./references#CD012040-fig-0008" title="">Analysis 1.6</a>). The studies are very similar, so there is no obvious explanation for this level of heterogeneity. </p> </section> </section> <section id="CD012040-sec-0066"> <h6 class="title">c. FVC (absolute values and relative change from baseline)</h6> <p>We deduced estimates for the mean relative change from baseline in FVC % predicted at each 8‐weekly time point, including week 48, from a graphical representation from the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study (supplementary figure 1 of the paper; <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). There was no estimated difference in the mean relative change from baseline in FVC % predicted at any time point (8, 16, 24, 32, 40 and 48 weeks); end of trial data at 48 weeks are presented in the analysis (MD 1.10%, 95% CI ‐1.97 to 4.17; P = 0.48; 1 trial, 232 participants; <a href="./references#CD012040-fig-0009" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD012040-sec-0067"> <h5 class="title">3. Adverse events</h5> <p>In the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial, more participants in the placebo than ataluren group experienced diarrhoea, nausea, pyrexia, upper respiratory tract infections, rhinitis, pulmonary exacerbations, cough, haemoptysis and oropharyngeal pain. Abdominal pain, vomiting, sinusitis, headache and productive cough occurred more frequently in the ataluren group (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> <p>In the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial, more adverse events in total were reported by participants receiving ataluren (905) than by those receiving placebo (768). However, more participants in the placebo group experienced pulmonary exacerbations (including severe exacerbations), influenza, pseudomonal infections and staphylococcal infections, whereas more participants in the ataluren group experienced viral upper respiratory tract infections, sinusitis, nasopharyngitis, rhinitis, pharyngitis, cough, haemoptysis, diarrhoea, abdominal pain, nausea and vomiting, and nephrolithiasis (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> <p>Regarding specific adverse events, we present details of these in <a href="./references#CD012040-fig-0010" title="">Analysis 1.8</a>. Oropharyngeal pain (as reported by <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> only) was less common in the ataluren group (RR 0.28, 99% CI 0.10 to 0.83). In <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>, a  higher number of participants in the ataluren group reported episodes of acute kidney injury (reported terms include renal failure, acute renal failure, renal impairment and hypercreatininaemia; RR 17.70, 99% CI 1.28 to 244.40). In contrast, <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> only reported a single incidence of acute renal failure in the ataluren group (although their definition of this is unclear). Combined data suggest a difference in the incidence of acute renal failure between treatment groups, but notably wide 99% CIs (RR 12.81, 99% CI 2.46 to 66.65;  P = 0.002, I<sup>2</sup> = 0%; 2 trials, 537 participants; <a href="./references#CD012040-fig-0010" title="">Analysis 1.8</a>). In an open‐label extension study of the Kerem study, no participants had clinically significant laboratory abnormalities, including renal function, after 192 weeks of taking ataluren (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). </p> <p>Both studies classified adverse events by severity as grade 1 (mild), grade 2 (moderate), grade 3 (severe) and grade 4 (life‐threatening or death); however, they did not specify the criteria for grade 1 to 3 classifications (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). It was not possible for us to determine which reported adverse events they would class as mild (therapy does not need to be discontinued) or moderate (therapy is discontinued and the adverse effect ceases). The trials reported on adverse events that required discontinuation of therapy under the heading 'severe (life‐threatening or debilitating, or that persist even after treatment is discontinued)'. </p> <section id="CD012040-sec-0068"> <h6 class="title">a. Mild adverse events (therapy does not need to be discontinued)</h6> <p>Individually, neither trial reported differences in grade 1 (mild) adverse events between the ataluren and placebo groups (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>: RR 0.88, 95% 0.49 to 1.57; 1 trial, 231 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>, and <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>: RR 1.43, 95% CI 0.82 to 2.49; 1 trial, 279 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>). Combined data also showed no difference in mild adverse events between groups (RR 1.14, 95% CI 0.77 to 1.70; P = 0.52, I<sup>2</sup> = 30%; 2 trials, 512 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>). </p> <p>An open‐label extension study of the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> study reported four (6.6%) mild adverse events in participants receiving ataluren for 192 weeks (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). </p> </section> <section id="CD012040-sec-0069"> <h6 class="title">b. Moderate adverse events (therapy is discontinued and the adverse effect ceases)</h6> <p>The trials did not report on adverse events that specifically required interruption of treatment. Neither <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> nor <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported a difference in grade 2 adverse events between the ataluren and placebo groups; combined data also showed no difference (RR 1.09, 95% CI 0.95 to 1.24; P = 0.22, I<sup>2</sup> = 53%; 2 trials, 512 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>). An open‐label extension of the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported 26 (42.6%) moderate adverse events in participants receiving ataluren for 192 weeks (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). </p> </section> <section id="CD012040-sec-0070"> <h6 class="title">c. Severe adverse events (life‐threatening or debilitating, or that persist even after treatment is discontinued) </h6> <p>There were no life‐threatening events reported in either trial (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported that eight participants from the ataluren group and three from the placebo group discontinued therapy due to adverse events. <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported that three participants receiving ataluren and four receiving placebo experienced adverse events that led to discontinuation. No further information was provided regarding the nature of these events. </p> <p>There was no difference between treatment groups in investigator‐defined grade 3 (severe) adverse events for the individual trials (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>: RR 0.62, 95% CI 0.37 to 1.03; 1 trial, 233 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>, and <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>: RR 0.65, 95% CI 0.38 to 1.10; 1 trial, 279 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>; participants may have had more than one adverse event). Combined data showed significantly fewer severe adverse events in participants in the ataluren than placebo groups (RR 0.63, 95% CI 0.44 to 0.92; P = 0.02, I<sup>2</sup> = 0%; 2 trials, 512 participants; <a href="./references#CD012040-fig-0011" title="">Analysis 1.9</a>).  </p> <p>Of note, an open‐label extension of the Kerem trial (not included in this review) reported 30 (49.2%) severe and one (1.6%) fatal adverse events in participants receiving ataluren for 192 weeks (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). </p> </section> </section> </section> <section id="CD012040-sec-0071"> <h4 class="title">Secondary outcomes</h4> <section id="CD012040-sec-0072"> <h5 class="title">1. Survival</h5> <section id="CD012040-sec-0073"> <h6 class="title">a. Time to event (death or lung transplant)</h6> <p>Both trials reported zero deaths and did not report on lung transplant (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0074"> <h6 class="title">b. Mortality rate</h6> <p>The trials reported zero deaths in both treatment groups (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> </section> <section id="CD012040-sec-0075"> <h5 class="title">2. Hospitalisation</h5> <p>No data were reported for hospitalisation in either trial (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>); one trial listed this outcome in the published protocol, but did not report data in the paper (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> </section> <section id="CD012040-sec-0076"> <h5 class="title">3. School or work attendance</h5> <p>Neither trial reported on school or work attendance (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>); one trial listed this outcome in the published protocol, but did not report data in the paper (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> </section> <section id="CD012040-sec-0077"> <h5 class="title">4. Extra courses of antibiotics</h5> <p>No data were reported specifically for extra courses of antibiotics (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported a pulmonary exacerbation rate, defined as extra courses of antibiotics in combination with four or more of Fuchs' signs and symptoms. Therefore, we do not report these data under this outcome and have presented these data under the following outcome, 'Pulmonary exacerbations'. The second trial listed this outcome in the published protocol, but did not report data in the paper (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). </p> </section> <section id="CD012040-sec-0078"> <h5 class="title">5. Pulmonary exacerbations</h5> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported on both physician‐defined (based on the individual physician's judgement) and protocol‐defined pulmonary exacerbation rates assessed using modified Fuchs' criteria. These criteria defined a pulmonary exacerbation as four of the following 12 symptoms, with or without treatment with antibiotics: change in sputum; new or increased haemoptysis; increased cough; increased dyspnoea; fatigue; temperature over 38 °C; anorexia; sinus pain; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10% or more from a previously recorded value; or radiographic changes indicative of pulmonary infection (<a href="./references#CD012040-bbs2-0028" title="FuchsHJ , BorowitzDS , ChristiansenDH , MorrisEM , NashML , RamseyBW , et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine1994;331:637-42. [DOI: 10.1056/NEJM199409083311003]">Fuchs 1994</a>). The <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial reported on protocol‐defined pulmonary exacerbation rates assessed using expanded Fuchs' criteria. The expanded Fuch's criteria differ from the modified Fuch's criteria in that they require the use of oral, inhaled or intravenous (IV) antibiotics, or a combination of these, in response to four or more of the above symptoms (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). Thus, we were not able to combine data. </p> <p><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported no treatment difference between the ataluren and placebo groups for either the physician‐ or protocol‐defined pulmonary exacerbation rate at up to 48 weeks (MD ‐0.02 (95% CI ‐0.67 to 0.63) and MD ‐0.36 (95% CI ‐0.89 to 0.17), respectively; <a href="./references#CD012040-fig-0012" title="">Analysis 1.10</a>). Of those who entered the open‐label extension phase of the Kerem trial (all taking ataluren), 68% experienced pulmonary exacerbations (assessed by modified Fuchs' criteria) over 192 weeks (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>). </p> <p><a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported no difference between treatment groups in protocol‐defined pulmonary exacerbation rates (no participants in this trial were receiving chronic inhaled aminoglycosides): MD ‐0.18 (95% CI ‐0.66 to 0.30; <a href="./references#CD012040-fig-0012" title="">Analysis 1.10</a>). </p> <section id="CD012040-sec-0079"> <h6 class="title">Subgroup analysis</h6> <p>In the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> subgroup analysis, the investigators reported a lower protocol‐defined pulmonary exacerbation rate with ataluren in participants not taking chronic inhaled tobramycin (MD ‐0.76, 95% CI ‐1.51 to ‐0.01) compared to no difference between the ataluren and placebo groups for those receiving chronic inhaled tobramycin (MD 0.36, 95% CI ‐0.28 to 1.00; <a href="./references#CD012040-fig-0013" title="">Analysis 1.11</a>).  </p> </section> </section> <section id="CD012040-sec-0080"> <h5 class="title">6. Radiological measures of lung disease</h5> <section id="CD012040-sec-0081"> <h6 class="title">a. Chest radiograph score</h6> <p>Neither trial reported on chest radiograph score (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0082"> <h6 class="title">b. CT score</h6> <p><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported on total lung CT scores and subscores at baseline, at the end of treatment (approximately 48 weeks) and the change from baseline. There was no difference in mean change in total lung CT score up to the end of treatment (approximately 48 weeks; MD ‐0.28, 95% CI ‐0.68 to 0.12; 1 trial, 203 participants; <a href="./references#CD012040-fig-0014" title="">Analysis 1.12</a>). </p> <section id="CD012040-sec-0083"> <p><b>Subgroup analysis</b></p> <p><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported no difference between ataluren and placebo in changes in total lung CT scores in a subgroup analysis according to inhaled tobramycin use (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). Data were not reported for the analysis. </p> </section> </section> </section> <section id="CD012040-sec-0084"> <h5 class="title">7. Acquisition of respiratory pathogens</h5> <p>The included trials did not report on this outcome (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0085"> <h5 class="title">8. Eradication of respiratory pathogens</h5> <p>No data were reported for the eradication of respiratory pathogens (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0086"> <h5 class="title">9. Nutrition and growth</h5> <section id="CD012040-sec-0087"> <h6 class="title">a. Weight</h6> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported no difference in the change in body weight between the ataluren and placebo groups over 48 weeks (difference 0.04 kg). Insufficient data were presented for inclusion in our analysis. </p> </section> <section id="CD012040-sec-0088"> <h6 class="title">b. Body mass index (BMI)</h6> <p>As with weight, the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial reported no statistically significant difference in change in BMI between treatment groups over 48 weeks (difference ‐0.108); further baseline and week 48 data were not reported, precluding any analysis. </p> <p><a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> reported no difference in change in BMI between ataluren and placebo over 48 weeks (MD ‐0.07, 95% CI ‐0.32 to 0.19; P = 0.62; 1 trial, 274 participants; <a href="./references#CD012040-fig-0015" title="">Analysis 1.13</a>). </p> </section> <section id="CD012040-sec-0089"> <h6 class="title">c. Height</h6> <p>Height was not reported in either trial (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> </section> <section id="CD012040-sec-0090"> <h5 class="title">10. Sweat chloride</h5> <p><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported no difference in change from baseline in sweat chloride between the ataluren and placebo groups at up to 48 weeks (MD ‐0.70, 95% CI ‐3.41 to 2.01; P = 0.61; 1 trial, 194 participants; <a href="./references#CD012040-fig-0016" title="">Analysis 1.14</a>). </p> </section> <section id="CD012040-sec-0091"> <h5 class="title">11. Cost‐effectiveness</h5> <p>The trials did not report on the cost of ataluren treatment for people with CF (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012040-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012040-sec-0092"></div> <section id="CD012040-sec-0093"> <h3 class="title" id="CD012040-sec-0093">Summary of main results</h3> <p>This review examined whether specific therapies for class I mutations (PTCs) improve clinically relevant outcomes in people with CF. Our search identified 56 references to 20 trials; we excluded 18 trials and included two trials (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). The included studies were both RCTs of parallel design and enrolled a total of 517 participants aged six years and over (range six to 53 years old) with documentation of the presence of a nonsense mutation in at least one allele of the <i>CFTR</i> gene. The trials compared 40 mg/kg/day (in divided doses) of orally administered ataluren to placebo for a duration of 48 weeks.  </p> <p>The <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial undertook a post hoc subgroup analysis of participants not receiving chronic inhaled tobramycin (n = 146) that demonstrated favourable results for ataluren. The second included trial was subsequent to the Kerem trial and was designed to prospectively assess the effects of ataluren in participants not receiving chronic tobramycin (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). However, the results from this later trial suggest that the perceived favourable results for ataluren in the subgroup analysis in the earlier trial are likely to have occurred by chance. Some aminoglycosides, including tobramycin and gentamicin, have previously been demonstrated to have the ability to mask the abnormal gene sequence, resulting in significant changes in the salt‐transporting defect towards normal (<a href="./references#CD012040-bbs2-0023" title="ClancyJP , BebökZ , RuizF , KingC , JonesJ , WalkerL , et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2001;163(7):1683-92.">Clancy 2001</a>; <a href="./references#CD012040-bbs2-0032" title="HowardM , FrizzellRA , BedwellDM . Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine1996;2(4):467-9.">Howard 1996</a>; <a href="./references#CD012040-bbs2-0043" title="WilschanskiM ,  YahavY ,  YaacovY ,  BlauH ,  BenturL ,  RivlinJ , et al. Gentamicin induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine2003;349(15):1433-41.">Wilschanski 2003a</a>). The mechanism of action for such aminoglycosides is thought to be similar to that of ataluren, in that they enable read‐through of class I mutations (PTCs; <a href="./references#CD012040-bbs2-0041" title="WelchEM , BartonER , ZhuoJ , TomizawaY , FriesenWJ , TrifillisP , et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature2007;447(7140):87-91.">Welch 2007</a>). It is possible that in the subgroup of participants in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial receiving chronic inhaled tobramycin, the aminoglycoside may have enabled read‐through of the abnormal gene sequence, and therefore they would not benefit further from ataluren.  </p> <p>Results from the two included trials showed that ataluren was no better than placebo for the review's primary or secondary outcome measures at up to 48 weeks (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). Neither trial reported a difference in CFQ‐R respiratory domain scores between treatment groups (<a href="./references#CD012040-fig-0003" title="">Analysis 1.1</a>). Furthermore, neither trial demonstrated any difference between groups in the improvement in measures of respiratory function at up to 48 weeks (relative or absolute change in FEV<sub>1</sub> % predicted and relative change in FVC % predicted; <a href="./references#CD012040-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD012040-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD012040-fig-0006" title="">Analysis 1.4</a>; <a href="./references#CD012040-fig-0007" title="">Analysis 1.5</a>; <a href="./references#CD012040-fig-0008" title="">Analysis 1.6</a>; <a href="./references#CD012040-fig-0009" title="">Analysis 1.7</a>). In the subgroup analysis of participants not on long‐term inhaled tobramycin, <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> reported a reduction in the decline in FEV<sub>1</sub> over 48 weeks in participants treated with ataluren (n = 72) compared with placebo (n = 74; MD 5.7%, 95% CI 1.71% to 9.69). However, the subsequent <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial designed to prospectively assess the effects of ataluren in participants not receiving chronic tobramycin showed no reduction in the decline in FEV<sub>1</sub>. Combined data at 48 weeks for mean absolute change in FEV<sub>1</sub> in participants not receiving chronic inhaled aminoglycosides demonstrated no difference between groups (MD 1.84, 95% CI ‐0.90 to 4.58) with considerable heterogeneity (I<sup>2</sup> = 65%; <a href="./references#CD012040-fig-0008" title="">Analysis 1.6</a>). There is no clear explanation for the degree of heterogeneity demonstrated between the two trials. </p> <p>It was difficult to translate the reported adverse events into the mild, moderate and severe categories proposed in our protocol because the events were not presented according to this characterisation. There were fewer reports of oropharyngeal pain recorded in the ataluren group than the placebo group (RR 0.28, 95% CI 0.10 to 0.83). Ataluren was associated with a higher rate of episodes of acute kidney injury (including reported terms renal failure, acute renal failure, renal impairment and hypercreatininaemia; RR 12.81, 95% CI 2.46 to 66.65). The adverse events profile of ataluren should be interpreted with caution because it is based on small numbers of participants and the trials were not powered to assess this outcome. </p> <p>Neither trial reported a difference between groups in pulmonary exacerbation rates (either physician‐ or protocol‐defined) or BMI over 48 weeks (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). However, in the subgroup of participants not on long‐term inhaled tobramycin, those treated with ataluren were seen to have reduced pulmonary exacerbation rates (protocol‐defined: MD ‐0.76, 95% CI ‐1.51 to ‐0.01; <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>), although this was not the case in the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial, which was designed to assess the effects of ataluren in participants not receiving chronic tobramycin. Combined data at 48 weeks in participants not receiving chronic inhaled aminoglycosides demonstrated no difference between ataluren and placebo in the rate of protocol‐defined pulmonary exacerbation rates (MD ‐0.35, 95% CI ‐0.76 to 0.05) with moderate heterogeneity (I<sup>2</sup> = 39%; <a href="./references#CD012040-fig-0013" title="">Analysis 1.11</a>).  </p> <p>One trial reported no difference between groups in sweat chloride concentration or change in total lung CT score over 48 weeks in the ataluren compared with placebo group (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>). The second trial reported no difference between groups in body mass index over 48 weeks (<a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). No deaths were reported in either treatment group by either trial, and the length and size of the trials precluded valid assessment of the impact of ataluren on survival. An open‐label extension trial of one of the studies has been completed and, although not eligible for full inclusion due to lack of randomisation and control, it reported one fatality in participants who took ataluren for 192 weeks (<a href="./references#CD012040-bbs2-0009" title="NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]">NCT02107859</a>).  </p> <p>Neither trial reported on hospitalisations, school or work attendance, extra courses of antibiotics, chest radiograph scores, the acquisition or eradication of respiratory pathogens, height or cost‐effectiveness (<a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a>; <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a>). </p> </section> <section id="CD012040-sec-0094"> <h3 class="title" id="CD012040-sec-0094">Overall completeness and applicability of evidence</h3> <p>The included trials recruited a mixture of adults and children with CF with nonsense mutations across 124 sites internationally. Participants in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial had a mean age of 23 years, with 32% of participants aged under 18 years. In the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial, the mean age was 22 years, with 41% of participants aged under 18 years. Nonsense mutations are a type of class I mutation (PTC), and the results can be assumed to be applicable to individuals with nonsense CF mutations not included in this trial. Of note, however, is that the trials did not enrol participants aged under six years, pregnant women or those with stop codon mutations (another form of class I mutation (PTCs)). There are no data for outcomes that we considered important for this review: hospitalisation, school or work attendance, extra courses of antibiotics, chest radiograph score, acquisition or eradication of respiratory pathogens and cost‐effectiveness. </p> </section> <section id="CD012040-sec-0095"> <h3 class="title" id="CD012040-sec-0095">Certainty of the evidence</h3> <p>Please see the <a href="./full#CD012040-tbl-0001">summary of findings Table 1</a>. </p> <p>The trials were RCTs, which represent the highest quality with regard to trial design. The trials included a total of 517 participants and were well powered for one of the review's primary outcomes (change in FEV<sub>1</sub> % predicted). The randomised phase of the trials lasted 48 weeks and participants from the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial were entered into an open‐label extension trial that lasted a total of 192 weeks (the open‐label extension results were not included in this review). We judged the risk of bias to be moderate overall, with well‐documented random sequence generation, allocation concealment and blinding of trial personnel. Blinding of participants was less clear, because details of orally administered placebo versus ataluren (e.g. taste and consistency) were not provided. The risk of selective reporting in the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial was generally high because the trial did not always report on outcomes outlined in the protocol, present data for all outcomes and report on outcomes that we considered important. The trials were sponsored by the manufacturer of ataluren, PTC Therapeutics Incorportated, and some trial authors declared a financial interest. In the <a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> trial, eight of 27 authors are employees of PTC Therapeutics Incorportated and hold financial interests in the company; two authors received compensation for consultant services from PTC Therapeutics Incorportated during the trial; and four authors received compensation for travel expenses for meetings related to the trial. One author on the <a href="./references#CD012040-bbs2-0002" title="EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e] KonstanMW , DiMangoE , KeremE , MelottiP , RoweS , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] KonstanMW , VanDevanterDR , RoweSM , WilschanskiM , KeremE , Sermet-GaudelusI , et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: 31983658]McIntoshJ , VanDevanterDR . Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology2016;51(Suppl 45):280. [CFGD REGISTER: BD239b] NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d] ">Konstan 2020</a> trial is an employee of PTC Therapeutics Incorporated; three authors received compensation for consultation services from PTC Therapeutics Incorportated prior to or during the trial (or both); and four authors received compensation for travel expenses for meetings related to the trial. </p> <p>Overall, we judged the certainty of the evidence to be moderate (<a href="./full#CD012040-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD012040-sec-0096"> <h3 class="title" id="CD012040-sec-0096">Potential biases in the review process</h3> <p>Two review authors (AA and CH for the first review; AA and IS for this review update) independently applied inclusion and exclusion criteria to references identified through a comprehensive literature search. We then independently extracted data and assessed the risk of bias in the included trials. If any disagreement had arisen as to the risk of bias of the trial, we would have attempted to reach a consensus by discussion, failing which, a third author (KS) would have arbitrated. The analysis was undertaken by one review author (AA). This methodological approach ensured that risks of bias in the review process were kept to a minimum. This review has assessed all available published trial data. We contacted trial authors for relevant unpublished information and individual participant data. None have been made available to date. We are not aware of any unpublished trials, although we have highlighted issues with selective reporting in the included trials. </p> <p>We planned to include cross‐over trials if results from the first treatment arm were available. Independently assessing the only relevant cross‐over trial that we identified, we were unable to extract its data and therefore contacted the investigators. Because we did not receive any response from the investigators, we have excluded this trial (<a href="./references#CD012040-bbs2-0017" title="PradalU , CasottiV , DelmarcoA , NicolisE , LivraghiA , ConeseM , et al. Effects of gentamicin on ion transport, mRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology2002;34, Issue S24:263. [CENTRAL: 404061] [CFGD REGISTER: BD145] ">Pradal 2002</a>). We are aware that this reduces the number of trials we could include in the review. We acknowledge that the primary outcome for the included trials was relative change in FEV<sub>1</sub> % predicted, and therefore they may not be powered to detect a difference in our other primary outcomes, QoL and adverse events. Therefore, an absence of evidence of a difference in QoL or for the majority of adverse events does not rule out that ataluren may improve QoL or have a higher adverse event profile compared with placebo. </p> </section> <section id="CD012040-sec-0097"> <h3 class="title" id="CD012040-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>Two trials were eligible for inclusion in this review. In future, should further trials become eligible, we will update this review.  </p> <p>We are not aware of any other published systematic reviews of ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for CF. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012040-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD012040-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012040-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 1: QoL score (measured using CFQ‐R) ‐ change from baseline" data-id="CD012040-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 1: QoL score (measured using CFQ‐R) ‐ change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 2: FEV1 % predicted ‐ mean relative change from baseline" data-id="CD012040-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 2: FEV<sub>1</sub> % predicted ‐ mean relative change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 3: FEV1 % predicted ‐ mean relative change from baseline: subgroup analysis of participants not receiving chronic inhaled tobramycin" data-id="CD012040-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 3: FEV<sub>1</sub> % predicted ‐ mean relative change from baseline: subgroup analysis of participants not receiving chronic inhaled tobramycin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 4:  FEV1 % predicted ‐ mean relative change from baseline: subgroup analysis of participants receiving chronic inhaled tobramycin" data-id="CD012040-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 4:  FEV<sub>1</sub> % predicted ‐ mean relative change from baseline: subgroup analysis of participants receiving chronic inhaled tobramycin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 5: FEV1 % predicted ‐ mean absolute change from baseline" data-id="CD012040-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 5: FEV<sub>1</sub> % predicted ‐ mean absolute change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 6: FEV1 % predicted ‐ mean absolute change from baseline: subgroup of participants not receiving chronic inhaled tobramycin" data-id="CD012040-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 6: FEV<sub>1</sub> % predicted ‐ mean absolute change from baseline: subgroup of participants not receiving chronic inhaled tobramycin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 7: FVC % predicted ‐ mean relative change from baseline" data-id="CD012040-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 7: FVC % predicted ‐ mean relative change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 8: Specific adverse events (at up to 48 weeks)" data-id="CD012040-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 8: Specific adverse events (at up to 48 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 9: Severity of adverse effects of therapy as graded by trial authors" data-id="CD012040-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 9: Severity of adverse effects of therapy as graded by trial authors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 10: Pulmonary exacerbation rate" data-id="CD012040-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 10: Pulmonary exacerbation rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 11: Protocol‐defined pulmonary exacerbation rate: subgroup analysis by chronic inhaled tobramycin use" data-id="CD012040-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 11: Protocol‐defined pulmonary exacerbation rate: subgroup analysis by chronic inhaled tobramycin use </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 12: Total lung computed tomography score ‐ mean change from baseline" data-id="CD012040-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 12: Total lung computed tomography score ‐ mean change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 13: Body mass index ‐ change from baseline" data-id="CD012040-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 13: Body mass index ‐ change from baseline</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012040-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/urn:x-wiley:14651858:media:CD012040:CD012040-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ataluren versus placebo, Outcome 14: Sweat chloride level ‐ change from baseline" data-id="CD012040-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_t/tCD012040-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Ataluren versus placebo, Outcome 14: Sweat chloride level ‐ change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/media/CDSR/CD012040/image_n/nCD012040-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012040-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ataluren versus placebo for people with cystic fibrosis with class I mutations (PTCs)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ataluren versus placebo for people with cystic fibrosis with class I mutations (PTCs)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> adults and children with CF with at least one class I mutation (PTC) </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> oral ataluren 40 mg/kg/day (in divided doses)  </p> <p><b>Comparison:</b> oral placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of </b> </p> <p><b>the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ataluren</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life: </b> </p> <p>mean change from baseline in </p> <p>CFQ‐R respiratory domain score </p> <p>Scale: age‐appropriate versions of the</p> <p>CFQ‐R questionnaire</p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between groups in CFQ‐R score.</p> <p> </p> <p>One trial reported that the score was 0.27 points higher in the ataluren group (3.55 points lower  </p> <p>to 4.10 points higher).</p> <p> </p> <p>The second trial reported no difference in CFQ‐R in either the 6‐ to 13‐year age group or the 14‐years‐and‐over age group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>506</p> <p>(2 studies)<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> <p> </p> <p>The second trial did not present data for analysis and we have reported their results directly from the paper. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function:</b> </p> <p>FEV<sub>1</sub> % predicted (relative change from baseline) </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) relative change from baseline in the placebo group was ‐5.5% (12.56%).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean relative change from baseline in the ataluren group was 2.97% higher (0.58 lower to 6.52 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> <p> </p> <p>We were unable to combine results for this outcome, but we were able to combine the results in one of the subgroup analyses. </p> <p>In the group of participants not receiving chronic inhaled aminoglycosides, the combined data showed no difference between groups (MD 1.84%, 95% CI ‐0.90 to 4.58; P = 0.19, I<sup>2</sup> = 65%; 2 trials, 399 participants). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events relating to treatment</b> </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Acute kidney injury was more common in the ataluren group (RR 12.81, 95% CI 2.46 to 66.65; P = 0.02; 2 trials, 517 participants). </p> <p> </p> <p>Oropharyngeal pain was more common in the ataluren group (RR 0.28, 95% CI 0.10 to 0.83; P = 0.02; 1 trial, 238 participants). </p> <p> </p> <p>There was no difference between groups for any other adverse events relating to treatment, including: diarrhoea; abdominal pain; vomiting; nausea; pyrexia; upper respiratory tract infections; sinusitis; rhinitis; headache; pulmonary exacerbation; cough; haemoptysis; nasopharyngitis; influenza; pharyngitis; and nephrolithiasis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were graded by severity (1 to 4); however, details of criteria for grade 1 to 3 classifications were not reported. Adverse events occurring in more than 10% of participants were reported. There was no difference between treatment groups for all other recorded adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary exacerbations: protocol‐defined </b> </p> <p> </p> <p>Scale: rate </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) protocol‐defined pulmonary exacerbation rate using modified Fuchs' criteria in the placebo group was 1.78 (2.15). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protocol‐defined pulmonary exacerbation rate using modified Fuchs' criteria in the ataluren groups was 0.36 lower (0.89 lower to 0.17 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) protocol‐defined pulmonary exacerbation rate using expanded Fuchs' criteria in the placebo group was 1.13 (2.52). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protocol‐defined pulmonary exacerbation rate using expanded Fuchs' criteria in the ataluren groups was 0.18 lower (0.66 lower to 0.30 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nutrition and growth:</b> change in weight (kg), BMI (kg/m<sup>2</sup>) or height (m) </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No differences were found between treatment groups for changes in body weight or BMI.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>506</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> <p> </p> <p>One trial reported data for BMI (MD ‐0.07, 95% CI ‐0.32 to 0.19); the second trial reported narratively. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sweat chloride level ‐ change from baseline</b> </p> <p> </p> <p>Scale: mmol/L</p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in the placebo group was ‐0.6 (10.27) mmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the ataluren group was 0.70 mmol/L lower (3.41 mmol/L lower to 2.01 mmol/L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data provided by investigators were analysed via MMRM analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality rate</b> </p> <p> </p> <p><b>Follow‐up:</b> 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Both trials reported zero deaths in both treatment groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI:</b> body mass index; <b>CF</b> : cystic fibrosis; <b>CFQ‐R</b>: Cystic Fibrosis Questionnaire ‐ Revised (<a href="./references#CD012040-bbs2-0037" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8. [DOI: 10.1378/chest.08-1190]">Quittner 2009</a>); <b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>ITT</b> : intention‐to‐treat; <b>MD</b> : mean difference; <b>MMRM</b> : mixed‐model repeated‐measures analysis (based on the average effect across all post‐baseline visits); <b>PTC</b> : premature termination codon; <b>RR</b> : risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> stated that 238 participants were randomised, 232 were included in the ITT population and 203 completed the study. It is unclear how many participants were evaluated for the outcome.<br/><sup>b</sup><a href="./references#CD012040-bbs2-0001" title="AjayiT , KonstanM , AccursoFJ , De BoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h] DaviesJC , TiddensHA , MalfrootA , HeijermanHG , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q] De BoeckC , HeijermanH , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]De BoeckK , HeijermanHG , DaviesJC , Sermet-GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p] DeBoeckK , Sermet-GaudelusI , KeremE , WilschanskiM , AccursoFJ , KonstanM , et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m] EUCTR2008-003924-52-FR. A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR (date first received 17 March 2009). [CFGD REGISTER: BD167x] KeremE , KonstanMW , De BoeckK , AccursoFJ , Sermet-GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine2014;2(7):539-47. [CENTRAL: 994980] [CFGD REGISTER: BD167l] [EMBASE: 2014458185]KeremE , Sermet-GaudelusI , HjelteL , De BoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study. Journal of Cystic Fibrosis2016;15(Suppl 1):S118. [ABSTRACT NO.: 264] [CENTRAL: 1157461] [CFGD REGISTER: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology2012;47(Suppl 35):312. [ABSTRACT NO.: 252] [CENTRAL: 921643] [CFGD REGISTER: BD167e] KeremE , WilschanskiM , De BoeckK , Sermet-GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10(Suppl 1):S17. [ABSTRACT NO.: 65] [CENTRAL: 848847] [CFGD REGISTER: BD167c] KeremE , WilschanskiM , MelottiP , Sermet-GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45(Suppl 33):314. [ABSTRACT NO.: 314] [CENTRAL: 848848] [CFGD REGISTER: BD167a] KeremE , WilschanskiM , Sermet-GaudelusI , De BoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13(Suppl 2):S70. [ABSTRACT NO.: 94] [CENTRAL: 996543] [CFGD REGISTER: BD167k] KeremE , WilschasnskiM , Sermet-GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12(Suppl 1):S15. [ABSTRACT NO.: WS7.5] [CENTRAL: 921641] [CFGD REGISTER: BD167g] KonstanM , RoweSM , AccursoFJ , KeremE , WilschanskiM , Sermet-GaudelusI , et al. Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2014;49(Suppl 38):311. [ABSTRACT NO.: 266] [CENTRAL: 1012388] [CFGD REGISTER: BD167m] KonstanMW , AccursoFJ , De BoeckK , KeremE , RoweSM , Sermet-GaudelusI , et al. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46(Suppl 34):295. [ABSTRACT NO.: 232] [CENTRAL: 848849] [CFGD REGISTER: BD167d] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , De BoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):298. [ABSTRACT NO.: 258] [CENTRAL: 921688] [CFGD REGISTER: BD167i] NCT00803205. Study of ataluren (PTC124™) in cystic fibrosis. clinicaltrials.gov/show/NCT00803205 (first received 5 December 2008). [CFGD REGISTER: BD167w] RoweS , Sermet-GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47(Suppl 35):290. [ABSTRACT NO.: 193] [CENTRAL: 921642] [CFGD REGISTER: BD167f] RoweSM , KonstanMW , AccursoFJ , De BoeckK , Sermet-GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology2013;48(Suppl 36):279. [ABSTRACT NO.: 207] [CENTRAL: 921748] [CFGD REGISTER: BD167j] Sermet-GaudelusI , TiddensH , MalfrootA , HeijermanH , KeremE , HjelteL , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function. European Respiratory Journal2016;48(Suppl 60):PA4869. [CENTRAL: CN-01360693] [CFGD REGISTER: BD167t] [DOI: 10.1183/13993003.congress-2016.PA4869] [EMBASE: 614780537]TaybiRA , BoschJ , BoumaN , JinF , McIntoshJ , KemnerM . Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks. Journal of Cystic Fibrosis2017;16(Suppl 1):S121. [CFGD REGISTER: BD167s] TiddensHA , AndrinopoulouER , McIntoshJ , ElbornJS , KeremE , BoumaN , et al. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study. PLoS One2020;15(11):e0240898. [CFGD REGISTER: BD167v] TiddensHA , BoumaN , BoschJ , JinF , McIntoshJ , KemnerM . Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial. Journal of Cystic Fibrosis2017;16(Suppl 1):S44. [CFGD REGISTER: BD167r] ">Kerem 2014</a> provided insufficient data to conduct analyses.<br/><sup>c</sup>Downgraded due to imprecision demonstrated by wide CIs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ataluren versus placebo for people with cystic fibrosis with class I mutations (PTCs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012040-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of mutations affecting CFTR production, structure and function</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Class</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Example mutation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Impact on CFTR structure and function</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G542X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the presence of a premature termination codon in the nucleotide sequence. Individuals have no CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phe508del (ΔF508)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A full‐length CFTR protein is produced, but is structurally abnormal and destroyed by the cell before it reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Individuals have no CFTR function under normal conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G551D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond ('switch on') to normal stimulation from the cell. This means there is no significant ion transport across the membrane. Individuals have no CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R347P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFTR is transported to the outer cell membrane and responds to normal stimulation, but functions at a low level because chloride ions do not cross the channel appropriately. Individuals have some residual CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A455E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual CFTR function. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CFTR: cystic fibrosis transmembrane conductance regulator</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of mutations affecting CFTR production, structure and function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/full#CD012040-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012040-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ataluren versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 QoL score (measured using CFQ‐R) ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐3.55, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 FEV<sub>1</sub> % predicted ‐ mean relative change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At up to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.86, 6.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 At up to 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐1.29, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 At up to 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐1.69, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 At up to 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [‐0.54, 6.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 At up to 40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐1.07, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [‐0.58, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 FEV<sub>1</sub> % predicted ‐ mean relative change from baseline: subgroup analysis of participants not receiving chronic inhaled tobramycin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At up to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [2.21, 9.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 At up to 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐1.94, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 At up to 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐2.52, 6.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 At up to 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.40 [1.08, 9.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 At up to 40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.03, 7.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [1.71, 9.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4  FEV<sub>1</sub> % predicted ‐ mean relative change from baseline: subgroup analysis of participants receiving chronic inhaled tobramycin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 At up to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐4.02, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 At up to 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐3.92, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 At up to 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐12.35, ‐1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 At up to 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐7.88, 4.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 At up to 40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐7.23, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐8.15, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 FEV<sub>1</sub> % predicted ‐ mean absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [‐0.43, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 FEV<sub>1</sub> % predicted ‐ mean absolute change from baseline: subgroup of participants not receiving chronic inhaled tobramycin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [‐0.90, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 FVC % predicted ‐ mean relative change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At up to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐0.37, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 At up to 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐1.93, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 At up to 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐1.69, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 At up to 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐1.53, 5.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 At up to 40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐1.79, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐1.97, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Specific adverse events (at up to 48 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.84, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.81, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.56, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.47, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Viral upper respiratory tract infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.7 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.70, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.8 Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.61, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.9 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.10 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.75, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.11 Acute kidney injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.81 [2.46, 66.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.12 Pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.13 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.62, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.14 Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.51, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.15 Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.49, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.16 Oropharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.10, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.17 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.50, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.18 Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.32, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.19 Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.48 [0.73, 16.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.20 Nephrolithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.95 [0.36, 133.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Severity of adverse effects of therapy as graded by trial authors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Grade 1 (mild)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.77, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Grade 2 (moderate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.95, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Grade 3 (severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Grade 4 (life‐threatening or death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Pulmonary exacerbation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Physician‐defined pulmonary exacerbation rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.67, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Protocol‐defined pulmonary exacerbation rate (as defined by modified Fuchs' criteria) overall </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.89, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Protocol‐defined pulmonary exacerbation rate (as defined by expanded Fuchs' criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.66, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Protocol‐defined pulmonary exacerbation rate: subgroup analysis by chronic inhaled tobramycin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Participants not receiving chronic inhaled tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.51, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Participants receiving chronic inhaled tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐0.28, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Total lung computed tomography score ‐ mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.68, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Body mass index ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.32, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Sweat chloride level ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 At up to 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐3.41, 2.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ataluren versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012040.pub3/references#CD012040-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012040.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012040-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012040-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012040-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012040-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012040-note-0006">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012040-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012040-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012040\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012040\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012040\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012040\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012040.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012040.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012040.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012040.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012040.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718959478"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012040.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718959482"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012040.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddd0e3ca91be5',t:'MTc0MDcxODk1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 